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Abstract 12 
In Gram-negative bacteria, outer membrane lipoproteins are essential for maintaining cellular 13 
integrity, transporting nutrients, establishing infections and promoting the formation of biofilms. The 14 
LolCDE ABC transporter, LolA chaperone, and LolB outer membrane receptor form an essential 15 
system for transporting newly-matured lipoproteins from the outer leaflet of the cytoplasmic 16 
membrane to the innermost leaflet of the outer membrane. Here, we present a crystal structure of LolA 17 
in complex with the periplasmic domain of LolC. The structure reveals how a solvent-exposed β-18 
hairpin loop (termed the ‘Hook’) and trio of surface residues (the ‘Pad’) of LolC are essential for 19 
recruiting LolA from the periplasm and priming it to receive lipoproteins. Experiments with purified 20 
LolCDE complex demonstrate that association with LolA is independent of nucleotide binding and 21 
hydrolysis, and homology models based on the MacB ABC transporter predict that LolA recruitment 22 
takes place at a periplasmic site located at least 50 Å from the inner membrane. Implications for the 23 
mechanism of lipoprotein extraction and transfer are discussed. The LolA·LolC structure provides 24 
atomic details on a key protein interaction within the Lol pathway and constitutes a vital step toward 25 
the complete molecular understanding of this important system. 26 
 27 
Significance 28 
The outer membrane of Gram-negative bacteria presents a selectively-permeable barrier to the 29 
environment and is the first line of defence against antibiotics and other antimicrobial agents. 30 
Maintenance of the outer membrane relies on lipoproteins delivered by the LolABCDE system making 31 
the Lol proteins attractive targets for the development of new antimicrobial compounds. During 32 
trafficking, lipoproteins are extracted from the cytoplasmic membrane by the LolCDE complex, 33 
transported across the periplasm by LolA and integrated into the outer membrane by LolB. Here, we 34 
describe structural features underpinning the interaction between LolA and LolCDE. The structure of 35 
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LolA bound to the periplasmic domain of LolC provides an arresting molecular snapshot of a key 36 
intermediate in the bacterial lipoprotein trafficking pathway. 37 
 38 
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Introduction 43 
In Gram-negative bacteria, the outer membrane provides an important physical barrier to the 44 
extracellular space protecting against osmotic shock, noxious compounds and antibiotics (1, 2). 45 
Lipoproteins, anchored by N-terminally linked acyl groups, are a crucial structural component of the 46 
outer membrane maintaining attachment to the peptidoglycan layer (3, 4). Other lipoproteins underpin 47 
assembly of integral β-barrel proteins at the outer membrane (1, 5, 6), insertion of lipopolysaccharide 48 
(7, 8), maintenance of outer membrane lipid asymmetry (9, 10) and regulation of peptidoglycan 49 
synthesis (11). Lipoproteins are therefore central to the physiology of the cell envelope. 50 
Mislocalisation of outer membrane lipoproteins on the inner membrane results in cell death (12, 13) 51 
and proteins responsible for lipoylation and trafficking of outer membrane lipoproteins are essential 52 
for bacterial viability (14–18). The relative accessibility of proteins involved in lipoprotein maturation 53 
and trafficking, combined with their essential functions, have made these systems attractive targets for 54 
developing new antimicrobial agents (19–21).  55 
 56 
Maturation of bacterial lipoproteins is a multistep process (Fig. 1). Lipoproteins are first produced in 57 
‘prepro’ form in the cytoplasm and require transport across the inner membrane by the Sec pathway 58 
(22). Once integrated into the membrane, preprolipoproteins are subject to a series of modifications by 59 
enzymes recognising a cluster of four sequential amino acids termed the lipobox (22). Addition of the 60 
fatty acyl groups is accomplished by the sequential action of three enzymes: Lgt, Lsp and Lnt. Firstly, 61 
Lgt catalyses addition of diacylglycerol to the lipobox cysteine residue before Lsp removes the N-62 
terminal transmembrane anchor. Finally, Lnt acetylates the N-terminal amino group of the cysteine 63 
resulting in the mature, triacylated, form (22). Lipoproteins bearing an aspartate at position 2 of the 64 
lipobox are retained in the inner membrane (23), and mature lipoproteins destined for the outer 65 
membrane are transported by the Lol system, which, in E. coli, is composed of five proteins, 66 
LolABCDE (14, 15, 24).  67 
 68 
The LolCDE complex is an ABC transporter that comprises a heterodimer of the transmembrane 69 
proteins LolC and LolE, and a homodimer of cytoplasmic LolD, which forms the nucleotide binding 70 
domain (NBD) that hydrolyses ATP. LolCDE is responsible for the energetically costly extraction of 71 
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lipoproteins from the inner membrane and their transfer to LolA, a periplasmic chaperone. 72 
Lipoproteins bound to LolA are transported across the periplasm and accepted by the outer membrane 73 
receptor LolB, itself a lipoprotein, which mediates substrate integration into the outer membrane (14, 74 
16). Though E. coli LolA and LolB have similar β-barrel folds (25), they perform distinct roles (26). 75 
 76 
Transfer of lipoproteins between LolA and LolB is proposed to proceed by ‘mouth-to-mouth’ 77 
exchange between the central barrels of these proteins (27). NMR and in vivo crosslinking 78 
experiments support the mouth-to-mouth model through identification of contacting residues in LolA 79 
and LolB that map to the rim of the barrel during complex formation (27, 28). In vivo crosslinking 80 
studies have also demonstrated that in E. coli, LolC and LolE have distinct roles. LolC interacts with 81 
the LolA chaperone while LolE binds lipoproteins, but the molecular details of these interactions are 82 
not clear (27, 29). In other organisms, including pathogens such as Francisella tularensis and 83 
Acinetobacter baumannii, such division of labour does not exist and LolF replaces both LolC and 84 
LolE in a symmetric, LolDF assembly (30). 85 
 86 
The LolCDE complex belongs to the ABC3 superfamily of ABC transporters, which includes the 87 
tripartite efflux pump component MacB and the FtsEX cell division machinery (31, 32). Unlike 88 
canonical ABC transporters, ABC3 members (also known as Type VII ABC transporters) (33) are not 89 
proposed to transport substrates across the membrane in which they are embedded. At present, MacB, 90 
a toxin and antibiotic transporter (33–35), is the only representative of the ABC3 family to be 91 
structurally characterised (33, 36–38). Each monomer of the MacB homodimer has a distinctive 4-92 
transmembrane helix topology and an N-terminally fused NBD. A large periplasmic domain, 93 
composed of so-called Porter and Sabre subdomains is elevated ~25 Å above the membrane by a 94 
helical stalk composed of extensions of the first and second transmembrane helices (TM1 and TM2). 95 
A shorter periplamic loop, termed the Shoulder, links TM3 and TM4. Comparison of ATP-bound (33) 96 
and nucleotide-free (37) structures indicates that MacB undergoes impressive conformational changes, 97 
termed ‘mechanotransmission’, during its ATP binding and hydrolysis cycle. Mechanotransmission 98 
couples cytoplasmic ATP hydrolysis with periplasmic conformational changes used to perform work 99 
in the periplasm/extracytoplasmic space (33). LolC and LolE have the same transmembrane topology 100 
as MacB (39), and the periplasmic domain has the same fold, with both Sabre and Porter domains 101 
evident. It is therefore likely that the mechanotransmission mechanism also underpins extraction and 102 
transfer of lipoproteins from the inner membrane to the periplasmic LolA chaperone (33). 103 
 104 
In the present study, we define the interaction between LolCDE and LolA using a combination of 105 
structural, biochemical and microbiological techniques. Atomic details of LolC-LolA interaction are 106 
captured by X-ray crystallography and the mode of binding is probed and validated using site-directed 107 
mutagenesis. We also analyse the nucleotide dependence of LolA binding to LolCDE and evaluate 108 
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existing biochemical data in context of the complete LolCDE model based on the structure of MacB. 109 
Our data provide fundamental insights into bacterial lipoprotein trafficking and may assist the 110 
development or improvement of existing Lol-pathway inhibitors. 111 
 112 
Results 113 
Structure of LolA bound to the periplasmic domain of LolC. We determined the crystal structure 114 
of LolA in complex with the periplasmic domain of LolC at 2 Å resolution. Crystals of the LolA∙LolC 115 
complex belong to space group P21212 and contain two complexes per asymmetric unit. 116 
Representative electron density for the LolA∙LolC structure is shown in Movie 1 and X-ray data and 117 
refinement statistics are given in Table S1. The buried surface area of the LolA∙LolC complex is 118 
1950 Å2, which equates to 9 % of the total LolA surface. 119 
 120 
The structure of LolA in complex with the periplasmic domain of LolC is shown in Fig. 2A. The 121 
structures of isolated LolA (25) and the LolC periplasmic domain (33) have been described 122 
previously. LolA has a barrel-like fold comprised of an 11-stranded antiparallel β-sheet with a short 123 
helix located within its centre (25), and the LolC periplasmic domain shares its fold with the MacB 124 
ABC transporter (33). In the complex, LolC binds to LolA by means of a distinctive β-hairpin 125 
structure formed by residues P167-P179 (full-length LolC numbering) and a trio of surface residues 126 
(R163, Q181 and R182). We define the hairpin loop of LolC as the ‘Hook’ and the additional surface 127 
residues as the ‘Pad’. The tip of the Hook constitutes a classical type I reverse-turn with M175 and 128 
P174 at its apex (Fig. 2B). The tip residues make numerous hydrophobic interactions with LolA, 129 
including the side chains of F47, W49, L59, L66, L81, A84, F90, M91 and Y152. The backbone 130 
carbonyl of P174 forms a hydrogen bond with T88 of LolA. Hook residues F172, T173 and I178 also 131 
interact with residues in the LolA interior, but other residues in the Hook do not. The main chain of 132 
F172 is also involved in a hydrogen bonding network with Q22 and Q33 of LolA. The three residues 133 
of the Pad contribute to several intermolecular hydrogen bonds and R163 forms a salt bridge with 134 
D178 of LolA. 135 
 136 
The conformation of LolC is not perturbed by interaction with LolA (root-mean-square deviation 137 
(rmsd) of 0.77Å over 224 residues). Conversely, as a consequence of the interaction with LolC, the 138 
LolA chaperone undergoes several conformational changes that are revealed by structural 139 
superposition of the LolA·LolC complex with known structures of LolA determined in isolation. 140 
Figure S1 highlights four regions exhibiting large structural differences including per residue rmsd 141 
plots (Fig. S1A), their mapping to the LolA structure (Fig. S1B) and close-up structural comparisons 142 
(Fig. S1C-F). A molecular morph of LolA transiting between LolC-bound and -free states is shown in 143 
Movie 2. The key differences in the structures are the widening of the mouth of LolA and 144 
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displacement of the central helix. Most structural displacements in LolA can be attributed to 145 
interactions with the LolC Hook (Fig. S1C-E), but residues in the LolA C-terminus shift due to their 146 
interaction with the LolC Pad (Fig. S1F). 147 
 148 
The Hook and Pad of LolC are required for interaction with LolA. To assess the importance of 149 
the Hook and Pad in mediating complex formation between LolA and LolC, we made LolC 150 
periplasmic domain variants bearing point mutations in either the Hook or Pad and characterised their 151 
interaction with LolA using isothermal titration calorimetry (ITC) and size-exclusion chromatography 152 
(SEC). A representative ITC experiment for the interaction of LolA with wild-type LolC is presented 153 
in Fig. 3A with ITC data for the variants summarized in Fig. 3B, C. The thermodynamic properties 154 
extracted from each ITC experiment are given in Table S2 and example raw ITC data and fitted 155 
curves for each LolC variant are in Fig. S2. For wild-type LolC and LolA, we found that the complex 156 
is formed with high affinity (KD 405 nM) and has a one-to-one stoichiometry. ITC also shows that 157 
complex formation is entropy-driven (ΔH 7.3 and TΔS 16.0) confirming that hydrophobic interactions 158 
dominate the binding interface. Size-exclusion chromatography verifies complex formation between 159 
LolA and LolC, with an elution volume for LolA∙LolC corroborating the equimolar stoichiometry of 160 
the crystal structure and ITC experiments (Fig. 3D). 161 
 162 
In contrast to the wild-type, a designed LolC protein construct lacking the Hook (LolC ΔHook) does 163 
not form a stable complex with LolA that is detectable by either ITC or SEC (Fig. 3B, D). We solved 164 
the structure of this variant to demonstrate that the inability of LolC ΔHook to bind LolA is not due to 165 
loss of structural integrity (Fig. S3A). Corresponding X-ray data and refinement statistics for the LolC 166 
ΔHook protein construct are given in Table S1, and a close-up of the electron density defining 167 
residues in the shortened loop is given in Fig. S3B. LolC wild-type and ΔHook can be superposed 168 
with an rmsd of 0.57 Å for 207 matched Cα positions and inspection of the atomic coordinates reveals 169 
no obvious structural differences beyond the absence of the Hook itself (Fig. S3C). 170 
 171 
Having established the importance of the Hook for LolA binding, we next tested the relative 172 
importance of its constituent residues. Alanine substitutions of F172, M175, and R177 in the LolC 173 
Hook each give nearly 10-fold reductions in affinity for LolA, as measured by ITC (Fig. 3B, C & 174 
Table S2). T173A and I178A LolC variants are more substantially impaired (160-fold and 25-fold 175 
reductions) but the Q171A variant retains wild-type binding characteristics. The pattern of reduced 176 
affinity among alanine-substituted Hook variants correlates strongly with the reduction of favourable 177 
interactions between LolC and LolA expected from inspection of the LolA∙LolC crystal structure. 178 
Residues F172, T173, M175 and I178 all make important contributions to the LolA-binding interface 179 
that would be diminished by alanine substitution while Q171 does not make meaningful contact with 180 
LolA. Reasons for impaired binding by the R177A variant are not clear as R177 does not contact 181 
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LolA, however, interactions between R177 and other LolC Hook residues (F172 and S170) suggest a 182 
probable role in maintaining Hook structure. 183 
 184 
No individual alanine substitution in the Hook was sufficient to prevent binding of LolA to LolC, 185 
however an M175R variant lacks the capacity to bind LolA (Fig. 3B, C & Table S2). The location of 186 
M175 at the tip of the LolC Hook makes it a critical residue in the LolA∙LolC interface, and 187 
substitution with arginine disrupts both the hydrophobic character and size of the Hook. The LolC 188 
M175R variant is stable and purified in similar yield to wild-type suggesting loss of LolA binding is 189 
due to steric hindrance and unfavourable electrostatics of the M175R substitution rather than protein 190 
misfolding. 191 
 192 
The LolC Pad is significantly smaller than the Hook, but mutation of any of its three constituents 193 
(R163, Q181 and R182) reduces the affinity for LolA (Fig. 3B, C & Table S2). LolC Q181A and 194 
R182A variants exhibit 3- and 70-fold reductions in affinity, respectively. R163 is the most important 195 
Pad residue as the alanine variant is unable to bind LolA. Indeed, in the LolA∙LolC crystal structure, 196 
R163 forms a salt bridge with D178 of LolA while Q181 and R163 support interfacial hydrogen bonds 197 
(Fig. 2B). Overall, the ITC and SEC results demonstrate the importance of the LolC Hook and Pad in 198 
mediating interaction with LolA and highlight the roles of M175, T173, I178, R163 and R182 of LolC 199 
in the LolA∙LolC heterodimer interface. 200 
 201 
The Hook is conserved among LolC, LolE, and LolF proteins, but is absent from other ABC 202 
transporters belonging to the MacB ABC superfamily. To establish the generality of the Hook for 203 
interaction between LolC and LolA, we examined the amino acid sequences of LolC homologues. We 204 
found that a stretch of residues equivalent to the Hook is present in all LolC, LolE and LolF proteins 205 
analysed, but is absent from the MacB family of efflux pumps (including PvdT (40)) and the FtsEX 206 
cell division machinery (41, 42) (Fig. 4A). Inspection of periplasmic domain structures for LolC, 207 
LolF, FtsX and MacB confirm that this result holds for all available structural data (Fig. 4B). In 208 
conclusion, analysis of available homologous sequences and protein structures shows that the Hook is 209 
a conserved feature of lipoprotein trafficking machinery that is absent from other members of the Type 210 
VII ABC transporter superfamily. 211 
 212 
The Hook in LolE does not support LolA binding. The conservation of a loop of residues in LolE at 213 
an equivalent position to the LolC Hook compelled us to test whether LolE is also able to bind LolA. 214 
We performed SEC and ITC experiments using a LolE periplasmic domain construct to assess 215 
potential LolA binding under the same conditions we observed binding to LolC. We found no 216 
evidence that LolA is able to bind the LolE periplasmic domain (Fig. S5). This result is consistent 217 
with previous work showing that E. coli LolC and LolE have different functions (27, 29), and suggests 218 
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the specific amino acid sequence of the LolC Hook is crucial for its interaction with LolA. Inspection 219 
of the LolE sequence reveals substantial sequence divergence in the Hook and absence of a residue 220 
equivalent to R163 of the LolC Pad despite clear retention of both Porter and Sabre subdomains. We 221 
conclude that the interaction between LolA and the LolCDE complex occurs exclusively through LolC 222 
and not with LolE, even though LolE is likely to possess the same overall fold as LolC. 223 
 224 
LolC recognises features of LolA that are absent from LolB. LolA and LolB possess very similar 225 
protein folds (25) but it is not known how (or if) LolC is able to distinguish between these two 226 
proteins as binding partners. To address these questions, we evaluated the ability of soluble LolB to 227 
interact with the periplasmic domain of LolC by SEC (Fig. S6A) and an IMAC-based pull-down assay 228 
(Fig. S6B). We did not observe binding between LolC and LolB in either case - even though LolC is 229 
able to bind LolA under the same conditions. Relative to LolB, LolA has an extended C-terminus 230 
which is required for efficient LolA function (43). Our structure reveals that this C-terminal region 231 
contains the three residues, T176, D178 and Q180, that underpin interaction with the LolC Pad (Figs. 232 
2B & S6C, D). Sequence alignments confirm that the presence of a C-terminal extension is conserved 233 
among LolA proteins but absent from LolB (Fig. S6C, D) suggesting that LolC does discriminate 234 
between LolA and LolB, and that interaction between the LolC Pad and the C-terminus of LolA is 235 
essential for chaperone recruitment to the LolCDE complex. 236 
 237 
Structural determination of the F47E LolA variant reveals a domain-swapped dimer. Previous 238 
work has shown that an F47E LolA variant is defective in releasing lipoproteins from the bacterial 239 
inner membrane and tightly associates with proteoliposomes reconstituted with LolCDE (44). When 240 
expressed in vivo, F47E LolA impairs bacterial growth in a dominant negative fashion. Intrigued by 241 
the unusual phenotypic effects of the F47E LolA variant and its effect on the interaction of LolA and 242 
LolCDE, we further scrutinised this protein using biophysical methods. 243 
 244 
We first measured association of the LolA F47E variant with LolA using ITC and found a >2-fold 245 
higher affinity of LolC for the F47E variant (KD ~200 nM) compared to wild-type LolA (KD ~405 nM) 246 
(Fig. 5A). We then tried to rationalise this observation by inspecting the LolA∙LolC crystal structure. 247 
The F47 side chain is located within the LolA interior (Fig. 5B), and in the LolA∙LolC complex is 248 
approximately 4 Å from M175 of LolC. A substitution of glutamate for phenylalanine at position 47 249 
does not explain the higher affinity of the LolA variant for LolC because a polar residue would 250 
weaken otherwise favourable hydrophobic interactions with LolC. We therefore determined the crystal 251 
structure of the F47E variant (X-ray data and refinement statistics in Table S1). To our surprise, we 252 
found that the LolA F47E variant is a domain-swapped dimer (Fig. 5C, electron density in Movie 3). 253 
The N-terminal α-helix and first two β-strands from one monomer replace the equivalent elements in 254 
the other monomer and the substituting glutamate is shifted away from the LolA cavity into solvent. 255 
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The SEC elution profile of the F47E variant LolA confirms existence of the domain-swapped state in 256 
solution, although the peak is broader than that of the wild-type, and its apparent molecular weight (34 257 
kDa) is smaller than expected from theory (46 kDa) (Fig. 5D). Hypothesising that the domain-258 
swapped state of the F47E variant may contribute to its unusual properties, we analysed the F47E 259 
structure for features that explain its enhanced affinity for LolC. Inspection revealed that the β-strand 260 
on which F47E is located is shifted approximately 6 Å relative to that of the wild-type (Fig. 5E). The 261 
displacement of this strand affects the position of residues F47, W49, M51 and Q53- all of which face 262 
the LolA barrel interior, and two of which (F47 and W49) are involved in binding LolC in the wild-263 
type protein. We therefore ascribe the ‘tight-binding’ properties of the F47E LolA variant to structural 264 
changes in the site that binds LolC resulting from a ‘strand slip’ induced by domain-swap 265 
dimerization. 266 
 267 
In vivo validation of the LolA·LolC interaction by mapping cross-link data. We mapped the 268 
locations of LolA residues previously tested for their capacity to form photo-inducible crosslinks with 269 
LolCDE (27) to our crystal structure of the LolA∙LolC complex (Fig. 6A). A full list of the Tokuda 270 
lab’s crosslinking results alongside nearest-neighbour distances measured from our crystal structure 271 
can be found in Table S3. There is excellent agreement between the in vivo crosslinking experiment 272 
and our crystal structure of the LolA∙LolC complex. All seven LolA residues that crosslink to LolC 273 
are located within the binding interface (Fig. 6A red). Conversely, residues identified as ineffective in 274 
forming crosslinks are positioned in regions that do not contact LolC (Fig. 6A blue). The mapping of 275 
previous cross-linking data to our crystal structure of the LolA∙LolC complex validates both 276 
approaches and confirms that the interface derived here by X-ray crystallography is representative of 277 
the state found in vivo. 278 
 279 
Mutations in the Hook and Pad of LolC suppress dominant-negative lolD alleles. We re-examined 280 
data on previously reported LolC and LolE variants that suppress the dominant-negative effects of 281 
mutations in the LolCDE ATPase component, LolD (45). These mutants map primarily, though not 282 
exclusively, to periplasmic region of LolC and to the cytoplasmic domains of LolE, suggesting they 283 
provide relief from growth arrest by different mechanisms. Our structure shows that two of the 284 
suppressor mutations, P174S and G176R, are located within the Hook of LolC and another two, 285 
R182C and R182H, are based within the Pad (Fig. 2B). Given the importance of the LolC Hook and 286 
Pad for LolA binding, our data predict that these four LolC periplasmic suppressors work by breaking 287 
the interaction between LolCDE and LolA to prevent accumulation of non-productive LolA·LolCDE 288 
complexes that otherwise lead to growth arrest. Putting these LolC suppressor mutations into a 289 
structural context highlights the importance of the Hook and Pad in mediating LolA recruitment by 290 
LolCDE, in vivo. 291 
 292 
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Disruption of the Lol system using knowledge of the LolA·LolC interaction. To further validate 293 
the interaction between LolA and LolC in vivo, we established an inducible plasmid-based system for 294 
expressing the LolC extracytoplasmic domain in the periplasm of E. coli with the intent of arresting 295 
growth through sequestration of LolA. Expression of the wild-type LolC extracytoplasmic domain in 296 
the periplasm produces growth arrest and cell lysis (Fig. 6B). Conversely, expression of variants 297 
lacking the Hook, or with single amino acid substitutions in the Hook (M175R) or Pad (R163A) that 298 
have been shown to abrogate the interaction between LolA and LolC in vitro, do not lead to growth 299 
defects (Fig. 6B) even though they are expressed at similar levels to the wild-type (Fig. 6C). These 300 
observations are consistent with growth arrest resulting from sequestration of periplasmic LolA by the 301 
overexpressed wild-type LolC periplasmic domain construct that can be relieved by mutations 302 
disrupting favourable interactions between LolA and the LolC Hook and Pad. 303 
 304 
LolA binding to LolCDE is mediated purely by access to the Hook and Pad and is independent 305 
of the ATP binding and hydrolysis cycle. To establish the behaviour of LolA binding within the 306 
context of the LolCDE complex, we immobilised detergent-purified LolCDE variants on Ni-IMAC 307 
resin and tested their ability to bind LolA. We also assayed each variant’s ATPase activity using a 308 
spectrophotometric assay. Results are summarized for each variant in Table 1 with the supporting data 309 
presented in Figure S7. We found that LolA binds to the wild-type LolCDE complex irrespective of 310 
the presence of nucleotide (Table 1, Fig. S7A, B) and that LolCDE exhibits equivalent ATPase 311 
activity in the presence and absence of LolA (Fig. S7C). Binding to LolA was also unaffected by 312 
mutation of a catalytic glutamate in LolD, or by the presence of a non-hydrolysable nucleotide 313 
analogue (ATPɣS) (Table 1, Fig. S7A). These results suggest that LolA binding to LolCDE is not 314 
dependent on the transporter nucleotide status, or its ability to hydrolyse ATP. Purified LolCDE 315 
complexes in which the LolC Hook was removed, or in which the Hook or Pad were disrupted 316 
maintain their ability to hydrolyse ATP, but are unable to bind LolA (Table 1, Fig. S7D, E). In 317 
contrast, deletion of the Hook in LolE does not impair LolA-LolCDE interaction (Table 1, Fig. S7D). 318 
We conclude that LolA binding to the LolCDE complex occurs exclusively through the Hook and Pad 319 
of LolC and is not regulated by nucleotide binding or hydrolysis.  320 
 321 
Modelling of the LolA·LolCDE complex in ATP-bound and nucleotide-free states. Due to 322 
established homology (33), the structure of LolCDE (and its complex with LolA) can be modelled on 323 
the basis of available crystal structures of MacB, the LolC periplasmic domain, and the LolA∙LolC 324 
complex. Such models are useful for contextualising the LolA-LolC interaction in three-dimensional 325 
space, giving clues as to the likely disposition of LolA relative to the membrane and other components 326 
of the LolCDE complex. We produced two distinct homology models of LolCDE corresponding to 327 
each of the different nucleotide states observed for the structural archetype of the family, MacB (33) 328 
(Fig. 7). The models show that binding of LolA to the LolCDE complex is feasible in both ATP-329 
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bound and nucleotide-free states just as we found in our in vitro binding experiments (Fig. S7). The 330 
models also predict LolA to be located approximately 60 Å from the cytoplasmic membrane with the 331 
‘mouth’ of the LolA barrel facing toward the LolE periplasmic domain. This result suggests that 332 
lipoproteins need not only be extracted from the inner membrane, but also passed a considerable 333 
distance to the waiting LolA chaperone on the top of LolCDE. While molecular details of lipoprotein 334 
transfer remain to be determined, the position and orientation of LolA are consistent with lipoprotein 335 
delivery via the central cavity between the periplasmic domains of LolC and LolE, perhaps aided by 336 
periplasmic conformational changes generated by mechanotransmission. 337 
 338 
Inhibition of LolCDE by Compound 2 proceeds by mechanotransmission uncoupling. Homology 339 
models of LolCDE and LolA∙LolCDE facilitate physical mapping of LolCDE mutations reported to 340 
provide resistance to two antimicrobial compounds: pyrrolopyrimidinedione ‘G0507’ (19) and 341 
pyridineimidazole ‘Compound 2’ (21) (hereon C2). G0507 and C2 are both purported inhibitors of 342 
LolCDE with potent antibacterial activity against E. coli strains lacking the tripartite efflux pump 343 
component, TolC. The majority of rescuing mutations for both G0507 and C2 cluster within the ‘stalk’ 344 
and ‘shoulder’ regions of the LolCDE complex, which are spatially close to one another despite 345 
separation in primary sequence (Fig. 7, right). In MacB, stalk structure is intimately connected with 346 
mechanotransmission suggesting that G0507 and C2 exert their effects by interfering with analogous 347 
movements necessary for coupling LolCDE’s cytoplasmic ATPase activity with the lipoprotein 348 
transfer reaction. Consistent with this ‘mechanotransmission uncoupling’ as a hypothesis for the action 349 
of these inhibitors, G0507 is known to stimulate ATPase activity of LolCDE while inhibiting the 350 
release of lipoproteins from the inner membrane (19). Since C2 also inhibits lipoprotein release, we 351 
tested its effect on LolCDE ATPase activity and found that, like G0507, C2 causes an increase in the 352 
rate of hydrolysis (Fig. S8A). We also found that C2 does not have any detectable effect on LolA 353 
binding to the LolC periplasmic domain nor LolCDE, as judged by IMAC-based pull-down 354 
experiments, ruling out competition between the inhibitor and the chaperone as an alternative 355 
hypothesis (Fig. S8B, C). 356 
 357 
Discussion 358 
We solved the crystal structure of the periplasmic lipoprotein chaperone, LolA, in complex with the 359 
extracytoplasmic domain of LolC (Fig. 2). LolC recruits LolA by means of a finger-like protrusion 360 
that we term the Hook and a patch of surface residues termed the Pad. Isothermal titration calorimetry 361 
and size-exclusion chromatography, coupled with structure-led amino acid substitutions in LolC, 362 
demonstrate the importance of these features (Fig. 3) and sequence-based analyses show that the Hook 363 
is conserved among LolC proteins but absent from homologous ABC transporters (such as MacB, 364 
PvdT and FtsEX) that do not have a lipoprotein trafficking function (Fig. 4). We uncovered the 365 
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structural basis for enhanced affinity of the LolA F47E variant (Fig. 5) and validated the native 366 
LolA∙LolC interface in vivo using crosslinking data from the Tokuda lab and a growth inhibition assay 367 
(Fig. 6). The interaction between LolC and LolA was confirmed for the detergent-purified LolCDE 368 
complex and was demonstrated to be independent of nucleotide binding and hydrolysis (Table 1). 369 
Modelling of LolCDE based on crystal structures of the MacB ABC transporter and LolC periplasmic 370 
domain predicts the likely structural context of the LolA-LolC interaction and implicates 371 
mechanotransmission in lipoprotein extraction and delivery to LolA (Fig. 7). The location of 372 
mutations that rescue LolCDE from the chemical inhibitors further suggest such compounds work by 373 
interfering directly with mechanotransmission, effectively uncoupling cytoplasmic ATP hydrolysis 374 
from periplasmic conformational changes necessary to drive lipoprotein transfer. The combined data 375 
give essential mechanistic insights into the progression of lipoproteins from inner membrane to the 376 
periplasmic LolA chaperone during lipoprotein trafficking. 377 
 378 
The key features of LolC that underpin binding of LolA are the Hook and Pad. Disruption of either 379 
causes substantial reduction in the affinity of LolA for LolC and complex formation is abrogated 380 
entirely if the Hook is deleted or if R163 of the Pad is replaced with alanine. These experiments 381 
demonstrate that the binding interface of LolC is bipartite and that neither Hook nor Pad alone is 382 
sufficient to mediate interaction with LolA. Comparison of the structure of the LolA∙LolC complex 383 
with that of LolA in isolation reveals significant conformational changes that suggest it may represent 384 
a ‘receptive state’ for lipoprotein binding. Several studies implicate the ‘mouth’ of the LolA barrel as a 385 
putative site for lipoyl group interaction (25, 27, 46, 47) meaning that both the Hook and lipoprotein 386 
may be in competition for the same binding site. If so, it is plausible that lipoprotein binding to LolA 387 
may directly cause release from LolC by displacement of the Hook. 388 
 389 
The work presented here establishes the interaction of LolA with LolC as independent of ATP binding 390 
and hydrolysis by the LolCDE complex. A key question for LolCDE, therefore, is what the role of 391 
energy input is, in vivo. Given nucleotide cycling is not required for LolA binding, the most likely role 392 
for ATP binding and hydrolysis is in driving lipoprotein extraction from the inner membrane. Efforts 393 
to determine the role of ATP binding and hydrolysis in the release of lipoproteins from LolCDE have 394 
been made previously (48, 49), but molecular details of this process remain obscure. One possibility is 395 
that ATP-powered extraction of lipoproteins from the inner membrane by the LolCDE complex uses a 396 
mechanotransmission mechanism as described for MacB (33). ATP-bound and nucleotide-free states 397 
of MacB have been structurally characterised, revealing long-range conformational changes and 398 
extensive periplasmic motions driven by ATP binding and hydrolysis. Similar motions in the LolCDE 399 
complex may provide the mechanical force needed to ‘pull’ the lipoprotein from the inner membrane.  400 
Our structural model suggests that LolA is bound as much as 60 Å from the inner membrane surface. 401 
Previous work has shown that LolE is the site of lipoprotein binding (29), but fine details of where the 402 
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interface is located are yet to be determined. Mechanotransmission-driven parting of the periplasmic 403 
domains in LolCDE might expose an intermediate lipoprotein binding site between LolC and LolE 404 
periplasmic domains that would provide a ‘stop-off point’ between the membrane and chaperone. 405 
Additional experiments will be required to test these hypotheses further. 406 
 407 
In summary, we have determined the crystal structure of LolA in complex with the periplasmic 408 
domain of LolC and probed the physical basis of the interaction using complementary techniques. We 409 
find that complex formation between LolA and LolC is independent of the LolCDE ATP binding and 410 
hydrolysis cycle and propose a mechanism where recruitment of LolA to the LolC Hook facilitates 411 
presentation to newly-extracted lipoproteins, possibly pulled from the membrane in an ATP-dependent 412 
manner by a mechanotransmission mechanism resembling that of the MacB ABC transporter.  413 
 414 
Methods 415 
Complete Supplemental Methods are available to download. In brief, structures of LolA bound to the 416 
LolC periplasmic domain, the LolA F47E variant, and LolC ∆Hook periplasmic domain were each 417 
determined by X-ray crystallography. Proteins were expressed in E. coli, purified using Ni-based 418 
immobilised metal affinity chromatography (Ni-IMAC) and crystallised using a sitting drop vapour 419 
diffusion setup. Crystals of the LolA·LolC complex were obtained in 100 mM HEPES pH 6.5 and 420 
45 % (w/v) poly(acrylic acid) 2100. LolA F47E was crystallised in 13 % (w/v) PEG 8000, 20 % (v/v) 421 
glycerol. The periplasmic domain of LolC ΔHook was crystallised in 30 % (w/v) PEG 2000 MME, 422 
200 mM ammonium sulfate, 150 mM sodium acetate pH 4.6, assisted by seeds from crystals of the 423 
wild-type LolC periplasmic domain obtained previously (33). Crystals were cryoprotected prior to 424 
flash freezing in liquid nitrogen using the reservoir solution supplemented with either 20 % ethylene 425 
glycol (LolA·LolC) or 25 % (v/v) glycerol (LolC ΔHook and LolA F47E). X-ray diffraction data were 426 
collected remotely at ESRF (France) and Diamond (UK) synchrotrons. Structure determinations used 427 
the CCP4 suite (50). Diffraction data were indexed and reduced with iMOSFLM (51), scaled with 428 
Aimless (52) and phased by molecular replacement using Phaser (53). Probes for molecular 429 
replacement were derived from PDB entries, 5NAA (33) and 1IWL (25). Model building and 430 
refinement used Coot (54) and Refmac (55). Structure validation was assisted by RAMPAGE (56) and 431 
Procheck (57). Size-Exclusion Chromatography (SEC) was performed using an Äkta FPLC equipped 432 
with a Superdex 75, 10/300 GL column. Typically, 100 μL of protein at 200 μM was analysed. 433 
Isothermal Titration Calorimetry (ITC) experiments were performed using a Microcal VP-ITC 434 
instrument. A typical titration used LolA in the cell (25 μM) and LolC variant in the syringe (300 or 435 
450 μM) with 30 x 10 μL-injections (reference power 25, 300 rpm stirring, 25 °C). LolA binding to 436 
His-tagged LolC periplasmic domain or LolCDE immobilised on IMAC resin was performed using 437 
microbatch spin columns. Immobilised proteins were incubated with tag-free LolA for ~5 min, washed 438 
three times, then eluted and visualised by SDS-PAGE. ATPase activity of purified LolCDE variants 439 
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was assessed using the EnzChek phosphate assay kit (Thermofisher) at 1 μM concentration. Purified 440 
LolCDE variants used dodecyl maltopyranoside as a stabilising detergent. The growth-inhibitory 441 
effect of extracytoplasmic targeting of the LolC periplasmic domain was assessed by monitoring 442 
OD600 of E. coli C43 (DE3) cultures (58) expressing the wild-type or variant domain fused behind an 443 
N-terminal Sec secretion signal. 444 
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Figure Legends 606 
 607 
Figure 1. Lipoprotein maturation and trafficking in E. coli. Steps 1-8 show a generic lipoprotein 608 
(LP) undergoing maturation and transport to the bacterial outer membrane (OM). (1) Immature 609 
lipoprotein is secreted by the Sec system and integrated in the inner membrane (IM). (2) Lgt adds 610 
diacylglycerol to the lipobox cysteine residue. (3) Lsp removes the transmembrane signal peptide. (4) 611 
Lnt acylates the lipoprotein N-terminus amino group. (5) LolCDE transfers the mature (triacylated) 612 
lipoprotein to the LolA chaperone. (6) Lipoprotein is passed from LolA to LolB by a 'mouth-to-mouth' 613 
mechanism. (7) LolA is recycled, leaving lipoprotein bound to LolB. (8) LolB releases lipoprotein to 614 
the outer membrane. 615 
 616 
Figure 2. Crystal structure of LolA bound to LolC periplasmic domain. (A) Overall structure of 617 
the LolA·LolC complex. (B) Close-up view of the interaction interface. LolC and LolA are shown in 618 
cyan and gold, respectively. LolC residues belonging to the Hook and the Pad are shown in purple and 619 
orange. LolA residues interacting with LolC are shown in stick representation. 620 
 621 
Figure 3. Isothermal titration calorimetry (ITC) and size-exclusion chromatography (SEC) 622 
experiments probing the LolA·LolC interface. (A) Representative ITC experiment demonstrating 623 
interaction between LolA and LolC. The main figure shows background-corrected heats of injection 624 
and a fitted binding curve (red). The two thermograms underpinning this curve are shown inset: 625 
injection of LolC into a cell containing LolA (top) and injection of LolC into buffer (bottom). (B) 626 
Association constants (KA) for wild-type and variant LolC periplasmic domains with LolA determined 627 
using ITC. Median values (μM-1) are indicated above each cluster of repeat experiments. Colouring is 628 
used to categorise binding strength of variants: wild-type-like binding, blue; modestly impaired, white; 629 
strongly impaired, yellow and non-binders, red. (C) Locations of amino acid substitutions in context of 630 
the LolC periplasmic domain (Hook purple and Pad orange). (D) SEC profiles for indicated proteins. 631 
 632 
Figure 4. Structural and bioinformatic evidence that the Hook is conserved among LolC, LolE 633 
and LolF but absent from the wider Type VII ABC Transporter superfamily. (A) Multiple 634 
sequence alignment comparing Lol-family proteins (LolC, LolE and LolF) with MacB and PvdT in the 635 
region of the Hook. Proline residues flanking the Hook are highlighted in yellow, and predicted 636 
β-sheets in blue. The full multiple sequence alignment is provided in Figure S4. Abbreviations are as 637 
follows: Ec, Escherichia coli; Aa, Aggregatibacter actinomycetemcomitans; Vc, Vibrio cholerae; Ng, 638 
Neisseria gonorrhoeae; Cj, Campylobacter jejuni; Pa, Pseudomonas aeruginosa; Se, Salmonella 639 
enterica serovar Typhimurium; Yp, Yersinia pestis; Hi, Haemophilus influenzae; Ab, Acinetobacter 640 
baumannii; Cb, Coxiella burnetii; Lp, Legionella pneumophila; Ft, Francisella tularensis; Bp, 641 
Burkholderia pseudomallei; Nm, Neisseria meningitidis; Hp, Helicobacter pylori; Gs, Geobacter 642 
sulfurreducens. (B) Comparison of the periplasmic domains of A. actinomycetemcomitans MacB 643 
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(5LIL), Mycobacterium tuberculosis FtsX (4N8N), E. coli LolC (5NAA) and A. baumannii LolF 644 
(5UDF, annotated as LolE in the PDB). LolC and LolF Hooks are shown in purple. FtsX lacks a Sabre 645 
domain, the remaining Porter is shown in blue and pair of helices at the location of the missing Sabre 646 
in grey. 647 
 648 
Figure 5. Structural and functional analysis of the 'tight-binding' LolA F47E variant. (A) ITC 649 
experiment demonstrating binding of LolA F47E to the LolC periplasmic domain. (B) Location of 650 
residue F47 in wild-type LolA. (C) Crystal structure of LolA F47E revealing a domain-swapped 651 
dimer. (D) Size-exclusion chromatography experiment for wild-type and LolA F47E variant. (E) 652 
Close-up view of LolA F47E variant showing the strand-slip affecting the location of residues E/F47, 653 
W49, M51 and Q53. LolA wild-type and F47E are in yellow and red respectively, LolC Hook shown 654 
in teal. 655 
 656 
Figure 6. In vivo validation of the LolA·LolC complex. (A) LolA positions determined to interact 657 
with LolC by in vivo crosslinking (27) mapped onto the LolA·LolC structure. LolC is represented in 658 
cyan with the Hook in purple. LolA is shown as a solid surface, residues reported to form crosslinks to 659 
LolC are coloured red, and those that do not are blue. (B) Growth curves for E. coli C43 (DE3) cells 660 
expressing the extracytoplasmic domain of wild-type LolC (or indicated variant) with a periplasmic 661 
targeting sequence. Protein expression was induced with 0.2 % arabinose at the time point indicated 662 
by an arrow. Curves depict the mean ± standard deviation for three independent cultures. (C) 663 
Immunoblot showing expression level of periplasmic extracts from E. coli C43 (DE3) cells bearing 664 
empty vector (Control), or expressing the extracytoplasmic domain of wild-type LolC (WT) or 665 
indicated variant. 666  667 
Figure 7. Homology-based models of the LolA·LolCDE complex. Models of full-length LolCDE 668 
generated from the nucleotide-free and ATP-bound structures of MacB (5NIL and 5LIL respectively). 669 
LolA has been docked according to LolA·LolC crystallographic data (6F3Z). Positions at which 670 
mutations confer resistance to both Compound 2 (21) and G0507 inhibitors (19) are shown mapped to 671 
the ATP-bound state. 672 
 
Table 1. LolCDE functional assays 
 
Protein LolA binding ATPase activity 
LolCDE (WT) + + 
LolC(ΔHook)DE - + 
LolC(R163A)DE - + 
LolC(M175R)DE - + 
LolCDE(ΔHook) + + 
LolCD(E171Q)E + - 
 
Raw data underpinning this table is provided in Figure S7. 
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Supplemental Figures 
 
 
 
 
Figure S1. Comparison of LolA in isolation and in complex with LolC. (A) Rmsd plots for 
superpositions of LolA in complex with LolC (6F3Z) with structures of LolA in isolation (1IWL and 
1UA8). Four regions with significant conformational differences are highlighted. (B) Structure of LolA 
colour-coded as per the rmsd plot. (C-F) Close-up views of LolA conformational differences in each 
region. Isolated LolA (1IWL) is shown in purple and the LolA·LolC complex is shown with LolC in 
teal and LolA coloured as in (B). 
  
3		
 
 
Figure S2. ITC titrations for LolA using wild-type or variant LolC periplasmic domain constructs. 
For each titration, a representative thermogram is shown in the upper part of the panel and fitted plot of 
background-subtracted heats of injection is shown immediately beneath. Values of affinities and 
thermodynamic parameters for all repeats are given in Table S2. 
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Figure S3. Removing the Hook from LolC does not disrupt its structure. (A) Crystal structure of 
the LolC ΔHook periplasmic domain construct. (B) Close-up view of the LolC ΔHook structure showing 
electron density for the linker residues (light grey) replacing the truncated Hook and surrounding β-
strands. The mesh represents a weighted 2ǀFoǀ-ǀFcǀ electron density map contoured at 1 sigma. (C) 
Alignment of LolC ΔHook (brown) and wild-type periplasmic domains (teal). Hook shown in red. 
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Conservation:                                               5              5 5  
E.coli AatP         1  -------------------------------------MLSFNMTTLHYYLKEALLNIIENRRQ-NFAFLV   32  
A.actino MacB     245  ----------------------------------FSKDQL------MEAFRMSVSAIVAHK---------  265  
E.coli MacB       249  ----------------------------------QFVSGF------NEALTMAWRALAANK---------  269 
V.cholerae MacB   254  ----------------------------------KLLDDF------REAFKMALLAMSNHR---------  274  
N.gonor MacB      243  -------------------------------SWSFYYDQF------VEAFRMSVQAVLAHK---------  266  
C.jejuni  MacB    241  ----------------------------------LLKNQA------FECFKIAYSSILAHK---------  261 
P.aeruginosa PvdT 268  ----------------------------------AWRAEL------LEAVRAAWRVMWINR---------  288  
 
E.coli LolC         1  -------------------------------------MYQ------PVALFIGLRYMRGRAA---DRFGR   24 
S.enterica LolC     1  MSAFFRITLTNSYGSDIYAFRFRLYTRDFANSNQTDYMYQ------PVALFIGLRYMRGRAA---DRFGR   61 
V.cholerae LolC     1  ---------------------------------MVGFMFH------PISAFIGLRYLRGRSG---DRFSR   28  
Y.pestis LolC       1  -------------------------------------MYQ------PVALFIGLRYMRGRAS---DRFGR   24 
H.influenzae LolC   1  -------------------------------------MNF------PISLYIALRYWRAKSA---DRFGR   24 
P.aeruginosa LolC   1  -------------------------------------MFR------PLSVFIGTRYTRAKRR---SHFVS   24 
 
E.coli LolE         1  -------------------------------------MAM------PLSLLIGLRFSRGRRR---GGMVS   24 
S.enterica LolE     1  -------------------------------------MAS------PLSLLIGLRFSRGRRR---GGMVS   24 
V.cholerae LolE     1  -------------------------------------MFS------SLALFIGGRFSRAKQR---NKMVS   24  
Y.pestis LolE       1  -------------------------------------MMGV----SPLSLLIGLRFSRGRRR---GGMVS   26 
H.influenzae LolE   1  -------------------------------------M--------NTPFFISWRYQRGKQK---NPLVA   22 
P.aeruginosa LolE   1  -------------------------------------MFR------PLPFFIGLRYTRAKRR---NHYIS   24 
 
A.baumannii LolF       ----------------------------------------------------------------------      
C.burnetii LolF     1  -------------------------------------MIR------PLALYVGLRYTRAKRR---NHFIS   24  
L.pneumo LolF       1  -------------------------------------MYK------PLALFIGLRYTRSRKK---NHFVS   24 
F.tularensis LolF   1  -------------------------------------MFK------SLPLFIGLRYIRAKKR---NRFIS   24  
B.pseudo LolF       1  -------------------------------------MKL------PYEWQIGWRYTRAGKRTTGNGFIS   27  
N.menin LolF        1  -------------------------------------MF-------SLEAWIGLRYLRAKKR---NGFMS   23  
H.pylori LolF       1  -------------------------------------MPN-----RSLIFFLIKRYLRFDKS---QPFIS   25  
G.sulfur LolF       1  -------------------------------------M--------PYELFIGLRYLKAKRK---STFIS   22  
 
Consensus aa:          ...............................................b.hbhthphh..pp.........  
Consensus ss:                                                         hhhhhhhhhhhh        hhh    
 
Conservation:            6  6  96 596 557  6656 8  
E.coli AatP        33  FLS-LSFIGVII-TDSLIYSVSLKA------EEE-LKVHSDKVIFVKFYRPK---------AVGYIM-EK   83  
A.actino MacB     266  MRSLLTMLGIIIGITSVVSVVALGNGSQQKILENIRGIGTNTMTIFNGNGFGDRRSRHIQNLKISDA-NT  334  
E.coli MacB       270  MRTLLTMLGIIIGIASVVSIVVVGDAAKQMVLADIRSIGTNTIDVYPGKDFGDDDPQYQQALKYDDL-IA  338 
V.cholerae MacB   275  LRTFLTMLGIIIGIASVVSVVALGNGSQKSILDSISSMGTSTIDVIPGTGFGDRRSGRVRTLTAADA-HA  343  
N.gonor MacB      267  MRSLLTMLGIIIGIASVVSVVALGNGSQKKILEDISSMGTNTISIFPGRGFGDRRSGKIKTLTIDDA-KI  335  
C.jejuni  MacB    262  LRSILTMLGIIIGIASVVCVVALGLGSQAKVLESIARLGTNTIEIRPGKGFGDLR-SGKTRLNFSDL-ET  329 
P.aeruginosa PvdT 289  FRTALTLLGIIIGVASVVVMLAVGEGSKRQVMAQMGAFGSNIIYLSGYSPNPRA---PMGIVSSDDV-AA  354  
 
E.coli LolC        25  FVSWLSTIGITLGVMALVTVLSVMNGFERELQNNILGLMPQAILSSEHGSL----------NPQQLP-ET   83 
S.enterica LolC    62  FVSWLSTIGITLGVMALVTVLSVMNGFERELQNNILGLMPQAILSAEHGSL----------NPNQMP-EK  120 
V.cholerae LolC    29  FVSYMSTAGITIGVMSLVTVLSVMNGFEAQLKSRILGVLPQAVVTEAAGKTT---------LSATPP-DF   88  
Y.pestis LolC      25  FVSWLSTIGITLGVMALITVLSVMNGFERNLQDTILGLMPQALITTPQGSLD---------PNKIPA-ST   84 
H.influenzae LolC  25  LVTNLASLGIVLGVMALIIVLSVMNGLEGYQKQQVLSSIPHAIVSEEQP-------------ISTEK-TL   80 
P.aeruginosa LolC  25  FISLTSMIGLALGVLVMIVVLSVMNGFDREMRTRILGMVPQATVESYQ-PID---------DWRALA-EK   83  
 
E.coli LolE        25  LISVISTIGIALGVAVLIVGLSAMNGFERELNNRILAVVPHGEIEAVDQPWT---------NWQEAL-DH   84 
S.enterica LolE    25  LISVISTIGIALGVAVLIVGLSAMNGFERELNNRILAVVPHGEIEAVNQPWT---------NWREAL-AK   84 
V.cholerae LolE    25  FISLSSTIGIAVGVAVIIIGLSAMNGFERELQTRVLSVIPHGEFEGVRGPVE---------RWPDLM-AQ   84  
Y.pestis LolE      27  LISVISTLGIALGVAVLIVGLSAMNGFERELKNRILAVVPHGEIAVVNQPFS---------GWPQTL-QR   86 
H.influenzae LolE  23  LIAKFSAIGIALGVAVLIVGLSAMNGFERELNQRILAVVPHAEILSAPNATEPTI-----HHWQNLE-KR   86 
P.aeruginosa LolE  25  FISLTSMIGLALGVLAMIIVLSVMNGFQKEMRTRILGMVPHATISAAQ-PLD---------DWQTVA-NA   83  
 
A.baumannii LolF    1  ------MVGLTLGVAVLITVLSVMNGFDRELKNRVLGMVPQATVSSTQ-ILT---------DWPELV-KR   53 
C.burnetii LolF    25  FISLVSMLGIALGVAVLITVLSVMNGFDYEIRTHFFALAPQVTVMTGQNIEK---------TWPELQ-KT   84  
L.pneumo LolF      25  FISLSSMLGIGMGVMVLITVLSVMNGFDQEIHRRFFGMAPEITITGPDERLS---------DWPEVV-KK   84 
F.tularensis LolF  25  IISAISFLGISLGVAVLITVMSVMNGFDQQIKSKILMMVPPLKVYQLGGEVT---------DWPNLAKEV   85  
B.pseudo LolF      28  FIAFVSMLGIALGVAALIVVLSVMNGFQKEVRDRMLSVLAHVEIFSPTGSMP---------DWQLTA-KE   87  
N.menin LolF       24  FITMVSIAGIALGVTALIVVLSVMNGFQKEIRGQLLNVAPHAEIGYIDNTDT---------DWRNLL-RF   83  
H.pylori LolF      26  ITALLAFFGVAVGVMVLIVAMAIMNGMSKEFEKKLFVMNYPLTLYTTS-PYG---------ISEEVV-QA   84  
G.sulfur LolF      23  IITFISTAGVALGVLALIVVLAVMTGFEEDLKEKILGTNAHIVVLKSSGGIE---------DYHAMM-ER   82  
 
Consensus aa:          h.ohhohlGlhlGlhsllhsltl.sG.pppl.ppl.sh.sp..h......................h.p.  
Consensus ss:          hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh      eeeee                hhhhh hh    
 
Conservation:                     8                       86  
E.coli AatP        84  FITVSKVLSF----SKNAFLYVSDTPFSGELFSVNGIDK-------------------------------  118  
A.actino MacB     335  LSKQSYIQSVTPNTSSSGILVVGN--KSFTSANLYGIGEQYFDVEGLKLKQG-RLLTE----------DD  391  
E.coli MacB       339  IQKQPWVASATPAVSQNLRLRYNN---VDVAASANGVSGDYFNVYGMTFSEG-NTFNQ----------EQ  394 
V.cholerae MacB   344  LSNLSFIDSVTPTLSTSVTIKYSN---QAVTASVQGVGPDYFRVRGYALADG-QYWDQ----------AS  399  
N.gonor MacB      336  IAKQSYVASATPMTSSGGTLTYRN---TDLTASLYGVGEQYFDVRGLKLETG-RLFDE----------ND  391  
C.jejuni  MacB    330  LRSLEYLEAVDAHSNTSGVATYTN---ISLSARAEGVGVNNFAIEGLRIDAG-RILNN----------DD  385 
P.aeruginosa PvdT 355  IATLPQVKKVMPVNGGELVVRYGN---IDYHAYVGGNNTDFPEILNWPVAEG-SYFTE----------RD  410  
 
E.coli LolC        84  AVKLDGVNRVAPITTGDVVLQSAR---SVAVGVMLGIDPAQKDPLTPYL----VNVKQ----------TD  136 
S.enterica LolC   121  AVNLQGVNRIAPLTTGDVVLQSAR---SVAVGVMLGIDPAQKDPLTPYL----VNVKQ----------SE  173 
V.cholerae LolC    89  VTALSTQRPPEPLVRSDAVVQSAS---QLAAGLLIGIEPQQNDPIEQHL----IAGRV----------TA  141  
Y.pestis LolC      85  LKSLSGVSDIVPLTTADVVLQSAR---NLAAGVMLGVDPQQHEPLANYL----VNVDI----------KA  137 
H.influenzae LolC  81  ENLPHFVQKAVPINTTNVIYQTAK---GVSAGQIIGIQSFSDDPLVESF----DQTKF---------NEI  134 
P.aeruginosa LolC  84  VKAHEHVTAVAPFTQMQGMLSANG---AVQTVMVDAVDPLEEAKVSIIPDFF-KQGSL----------AE  139  
 
E.coli LolE        85  VQKVPGIAAAAPYINFTGLVESGA---NLRAIQVKGVNPQQEQRLSALPSFV-QGDAW----------RN  140 
S.enterica LolE    85  VQKVPGIAAAAPYINFTGLVESGA---NLRAIQVKGVDPKQEQQLSALPSFV-QNHAW----------DH  140 
V.cholerae LolE    85  AARHPQIVAAAPYVKITALAESGT---QLKAIEVRGVDPQREQAVSRLSQFI-TAQAW----------QD  140  
Y.pestis LolE      87  IEKVPGIVAAAPYINFTGLIENST---QLRAVQVKGVDPEAEQHLSALPSFV-LDNAW----------SH  142 
H.influenzae LolE  87  LQQNPQIKGISPFVSFTALVENGS---KLKVVQVKGVEKQAEDKVSSIGNFV-QEQGW----------NK  142 
P.aeruginosa LolE  84  ALRHREVVGAAPFAELQGMLSYKG---NMLPVLVNGIDPQEERKVSIVGEHI-VQGSL----------DD  139  
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A.baumannii LolF   54  VENHPHVTGVAPFTQLQGMLTAQG---QVAGIMVTGIDPKYEKNVSIIQNHI-VAGSL----------DS  109 
C.burnetii LolF    85  IASNPEVVASAPFVTGMGLLSNEG---IVSGATVLGVVPSQEKKVSQLDGKL-VGGKL----------SS  140  
L.pneumo LolF      85  VETIPGIKAIAPYVGSQGLLTHEG---QVLPIVLTGILPEKEQSVTHLNKKL-LAGNM----------DN  140 
F.tularensis LolF  86  EKSTPSVTAVAPIVESQGLLSANSGSSTTAFVQIQGIEPKYQTKVLPIAEHI-VDGKL----------SS  144  
B.pseudo LolF      88  ARLNRSVIGAAPYVDAQALLTRQD---AVSGVMLRGVEPSLEPQVSDIGKDM-KAGAL----------TA  143  
N.menin LolF       84  TENRKGILAAAPYVSNQALLANAG---EIRGVQIRGILPSEERKVVEYGDKM-PAGKF----------ED  139  
H.pylori LolF      85  LEKKFPNLLFSPYLQTQSLIKSAH---SMNGGVVFGVDFSKEKRINEVLNDALKNINE----------ND  141  
G.sulfur LolF      83  LSAVKGVKAVTPFIYSQVMLSSGG---NVSGVVLRGVDPATDPQVTNLSRSL-VDGKLTDLTTVPAPLAS  148  
 
Consensus aa:          h.p...l..hsPhhp.pshlp.ss......s..l.Gl..p..p.hs...p......pb..........pp  
Consensus ss:          hh     eeeeeeeeeeeeeee     eeeeeeeeee hhhhhhhhhhhhhh     h          hh    
 
Conservation:                   566   5  7          7  5    5           8    5 7 6  
E.coli AatP       119  --------LGLNMGYAGDLNDK------YNGNVAVVNESSPFVSKKQIFINGVPFKIIGVRLNSKTDFLD  174  
A.actino MacB     392  VDQ-SNQVVVLDESAKKAIFANE---NPLGKTVIFN---------------KRPFRVIGVVSDQ-QLGG-  440  
E.coli MacB       395  LNG-RAQVVVLDSNTRRQLFPHK--ADVVGEVILVG---------------NMPARVIGVAEEK-QSMF-  444 
V.cholerae MacB   400  VET-LAQEAVIDNNTLKSLFPNQ---DPIGEVIFAG---------------NLPVRIIGVTKAK-ESAF-  448  
N.gonor MacB      392  VKE-DAQVVVIDQNVKDKLFADS---DPLGKTILFR---------------KRPLTVIGVMKKD-ENAF-  440  
C.jejuni  MacB    386  VKN-STNVAVLDFNAKKNLFPDEKSENILGRVVLFN---------------SQSFKIIGVLQKD-TDKP-  437 
P.aeruginosa PvdT 411  EDA-ATTVAVIGYKVRKKLFGSA---NPIGRYILIE---------------NVPFQVIGVLAEK-GSSS-  459  
 
E.coli LolC       137  LEP-GKYNVILGEQLASQLGVN------RGDQIRVMVPSASQFTPMGRIPSQRLFNVIGTFAAN-S----  194 
S.enterica LolC   174  LQP-GKYNVILGEQLAGQLGVN------RGDQIRLMVPSASQFTPMGRLPSQRLFTVIGTFAAN-S----  231 
V.cholerae LolC   142  LQA-GEYQLFLGHLLARSLNVT------VGDKVRLMVTEASQFTPLGRLPSQRNFTVAGIFNTG-S----  199  
Y.pestis LolC     138  LAP-GSYNIILGEKLAGQLGVK------RGETLRLMVPSASQFTPMGRIPSQRVFNIIGTFAAN-S----  195 
H.influenzae LolC 135  LPR-GEFKLVIGDQLAQKLGVN------IGDKIRLMITENSQYTPFGRVPMQRLFTVSDIYYGY-G----  192 
P.aeruginosa LolC 140  LKA-GGFGIVIGQLAAQKLGVG------IGDKVTLILPEVA-VTPAGVFPRMKRFTVVGTFRVGAG----  197  
 
E.coli LolE       141  FKA-GEQQIIIGKGVADALKVK------QGDWVSIMIPNSN-PEHKLMQPKRVRLHVAGILQLS-G----  197 
S.enterica LolE   141  FKA-GEQQIIIGKGVADALNVK------QGDWVSIMIPNAN-ADHKLLQPKRVRLHVIGILQLS-G----  197 
V.cholerae LolE   141  FRP-GQQQVILGQGVAEKLGVQ------VGDFITLMIPSAN-SGDKVQAPKRVRVKVSGLLALN-G----  197  
Y.pestis LolE     143  FKA-GQQQIILGKGLADTLGVK------QGDWLTVMIPNSD-PEMKLLQPKRIRLQVAGIFQLS-G----  199 
H.influenzae LolE 143  FE--KEGGLVLGSGIAKELDVK------VGDWITLLISQQN-GDEQFAQPTREPVQVTSILRLD-G----  198 
P.aeruginosa LolE 140  LKP-GEFGIVLGEITARRFHVN------VGDKLTLIVPEAT-SAPGGITPRMQRFTIVALFKVG-A----  196  
 
A.baumannii LolF  110  LKK-GEFGIVLGKDMADSLGLR------LNDSVTLVLPEAT-PSPAGVVPRFKRFKVVGIFSVG-A----  166 
C.burnetii LolF   141  LNP-GSYNIILGRKLADQLGLS------IGDKVSLFTPQTT-TTPLGIFPQFRRFTISGIFSTKSGF---  199  
L.pneumo lolF     141  L---KHFGIILGKGLADSLGVM------IGDKVTIMIPQAT-VTPAGMIPRFKRFTVVGVFSAGTGF---  197 
F.tularensis LolF 145  LDDNQGYNIVLGSVLADNLGVK------VGDKVTLIVPKIS-LTPAGMIPRIKQFRVSGIFSVS-Y----  202  
B.pseudo LolF     144  LAP-GQFGIVLGNALAGNLGVG------VGDKVTLVAPEGT-ITPAGMMPRLKQFTVVGIFESGHY----  201  
N.menin LolF      140  LIP-GEFDIILGVGLAEALGAE------VGNKVTVITPEGN-VTPAGVVPRLKQFTVVGLVKTGVY----  197  
H.pylori LolF     142  LFK-NPFNLIVGKSLRYSLNLD------LNQKADLFFTELE-PTGLTLSPIMKRFTIKGDFDSG-L----  198  
G.sulfur LolF     149  AEP-VRPGIIIGKELARSLNLY------VGDTLNVISPLGN-ITPLGMVPKMKQFRVVGLFNTGMF----  206  
 
Consensus aa:          h.....b.llls..h..pL.sp......hGc.l.l.hspss..s.....Pp...hpl.Glh.........  
Consensus ss:                 eeeeehhhhhh             eeeeee              eeeeeeeeeee            
 
Conservation:                                             5                                5   
E.coli AatP       175  SLGLKASQSDEHIFIPLETMFKMKLD--NRVNAVQIFLDNIVTKRDINNVKRVLYDNDIRKFDIVTSLNA  242  
A.actino MacB     441  -----FPGNSLNLYSPYSTVLNKITGG-SRIGSITVKISDDVNSTVAEKSLTELLKSLHGKKD-FFIMNS  503  
E.coli MacB       445  -----GSSKVLRVWLPYSTMSGRVMGQ-SWLNSITVRVKEGFDSAEAEQQLTRLLSLRHGKKD-FFTWNM  507 
V.cholerae MacB   449  -----GNSDSLNIWLPYTTVSARMMGQ-NYLDRISVRVNESTPSDAAEQAIISLLKMRHGTQD-FFTVNT  511  
N.gonor MacB      441  -----GNSDVLMLWSPYTTVMHQITGE-SHTNSITVKIKDNANTRVAEKGLAELLKARHGTED-FFMNNS  503  
C.jejuni  MacB    438  -----IEDNVVRLYIPYTTLMNKLTGD-RNLREIIVKVKDDVSSTLAENAIIRILEIKRGQKD-FFTFNS  500 
P.aeruginosa PvdT 460  ----GDKDADNRIAIPYSAASIRLFGT-RNPEYVIIAAADAQRVHQAERAIDQLMLRLHRGQRDYELTNN  524  
 
E.coli LolC       195  ------EVDGYEMLVNIEDASRLMRYPAGNITGWRLWLDEPLKVDSLSQQKL--------PEG-SKWQDW  249 
S.enterica LolC   232  ------EVDGYEMLVNIQDASRLMRYPAGNITGWRLWLDEPLQVDTLSQQTL--------PQG-TKWQDW  286 
V.cholerae LolC   200  ------DVDGQLMVTHLRDAAKLLRYDAQTISGWRLFFDDPFVVSQLAEQPL--------PQD-WQWSDW  254  
Y.pestis LolC     196  ------EVDGYQILVNQQDASRLMRYPLGNITGWRLFLSQPLSVDSLSQQSL--------PEG-TVWKDW  250 
H.influenzae LolC 193  ------EASGYEAFANITDIGRLMRIQPQQAQGYRLFLNDPFQITELPQHFPT-----------QKITDW  245 
P.aeruginosa LolC 198  ------ELDGGLSLIHLEDAARLQRWKTNQVQGLRLKLDDLFQAPRVAWEIARTLT----DND-FYARDW  256  
 
E.coli LolE       198  ------QLDHSFAMIPLADAQQYLDMG-SSVSGIALKMTDVFNANKLVRDAGEVT-----NSY-VYIKSW  254 
S.enterica LolE   198  ------QLDHSFAMIPLEDAQQYLDMG-SSVSGIALKVHDVFNANKLVRDAGEVT-----NSY-VYIKSW  254 
V.cholerae LolE   198  ------QIDHSLALLPLEDAQAYAHLG-SGVTGISVKVADVLQATQIVRDVGNQL-----NEY-VYLHSW  254  
Y.pestis LolE     200  ------QLDHSLALVPLIDAQQYLDMG-DSVTGIAIKVNDVYNANQLVRNAGEVS-----NAY-VYISSW  256 
H.influenzae LolE 199  ------QLDYSYALLPLAQAQTFLTYQPDQITGVELKLDDPFSARNLDLSMLNDY-----PQM-LYMQNW  256  
P.aeruginosa LolE 197  ------ELDNSLALIDIADAGQLLRLQPGQVPSVRLELKDLYQSPQVAAKVVKEL-----GQG-FRSSDW  254 
 
A.baumannii LolF  167  ------EVDSMVGYIALYDASTLLRLP-DGAQGVRLKLDDIFAAPQVADDIVKNL-----PSN-FYATNW  223 
C.burnetii LolF   200  ------GFDAGIAYINMQDGFRLFSQ---GASGLHIKIKNLYQAQSVTQQLQKLL-----PGE-FIVTNW  254  
L.pneumo LolF     198  ------NFDTKLAFINIEDAQKLMQMDKNDVSGIKMKINNVYKAPELSYELSDLL-----GEG-YQVGNW  255 
F.tularensis LolF 203  ------QYDAYYAMINIKDAQKVFETG-NSVSSLQLSVKNIYDAPLVKDKLNDGAI----PPY-YFTRDW  260  
B.pseudo LolF     202  ------EYDSTLAMIDIQDAQALFRLP--APTGVRLRLTDMQKAPQVARELAHTL-----SGD-LYIRDW  257  
N.menin LolF      198  ------EVDNSLAMTHIQDARVLYRLD-KEVAGLRLKLADPQNAPALTAKLIPEAQ----RDT-VWVRDW  255  
H.pylori LolF     199  -----KSYDMSYMYAGLQAISAIRRLPLGLYDGVHVYSKTPMKDIEILRNALKTIN----HHG-IGIEGW  258  
G.sulfur LolF     207  ------EYDSTLAYVGLGEAQEFLSMG-KAVTGIQLRVADVYHTGEMVREINRDL-----GFP-YYARDW  263  
 
Consensus aa:          ......p.s...hhhshpsh..bh....p.hstlpl.lps.hps..h.p.h.p.h.........h.h.sh  
Consensus ss:                     eeeeehhhhhhhh      eeeeeeee  hhhhhhhhhhhhhh          eeeeeh    
 
Conservation:          5                    5 755 86 575 5 7 5 8 57  77665 5 9     7   8  56  
E.coli AatP       243  KETVDRVLERFSLLTNSVYVILTLSASVTCF-ILSK--RSFYSRRVELSLKIIHGTEKKEITVLIIIESL  309  
A.actino MacB     504  DTIKQTIENTTGTMKLLISSIAFISLIVGGIGVMNIMLVSVTERTKEIGVRMAIGARQINILQQFLIEAV  573  
E.coli MacB       508  DGVLKTVEKTTRTLQLFLTLVAVISLVVGGIGVMNIMLVSVTERTREIGIRMAVGARASDVLQQFLIEAV  577 
V.cholerae MacB   512  DTIQKNIQKTTATMTLLISAIAVISLIVGGIGVMNIMLVSVTERTREIGVRMAVGARQNDILRQFLIEAV  581  
N.gonor MacB      504  DSIRQMVESTTGTMKLLISSIALISLVVGGIGVMNIMLVSVTERTKEIGIRMAIGARRGNILQQFLIEAV  573  
C.jejuni  MacB    501  DTFKQAITANKRTTTILTACVAVIALIVGGIGVMNIMLVSVSERTREIGIRMAIGARREDIMMQFLIEAV  570 
P.aeruginosa PvdT 525  AAMIQAEAKTQNTLSLMLGSIAAISLLVGGIGVMNIMLMTVRERTREIGIRMATGARQGDILRQFLTEAA  594  
 
E.coli LolC       250  RDRKGELFQAVRMEKNMMGLLLSLIVAVAAFNIITSLGLMVMEKQGEVAILQTQGLTPRQIMMVFMVQGA  319 
S.enterica LolC   287  RERKGELFQAVRMEKNMMGLLLSLIVAVAAFNIITSLGLMVMEKQGEVAILQTQGLTPRQIMMVFMVQGA  356 
V.cholerae LolC   255  REQRGELFQAVRMEKNMMGLMLGLIVGVAAFNIISALIMVVMEKQAEVAILKTQGMQSQHVLAIFMVQGA  324  
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Y.pestis LolC     251  RDRKGELFQAVRMEKNMMGLLLSLIIAVAAFNIITSLGLLVMEKQGEVAILQTQGLSRRQIMLVFMVQGA  320 
H.influenzae LolC 246  RVQKGEFFQAVRMEKNMMGLLISLIIVVAISNIVTSLSLMVVDKQGEIAILQTQGLTKSQVRSVFIYQGL  315 
P.aeruginosa LolC 257  TRSHGNLYQAIRMEKTMIGLLLLLIVAVAAFNIISTLVMVVTDKKSDIAILRTLGATPGQIMATFMVQGT  326  
 
E.coli LolE       255  IGTYGYMYRDIQMIRAIMYLAMVLVIGVACFNIVSTLVMAVKDKSGDIAVLRTLGAKDGLIRAIFVWYGL  324 
S.enterica LolE   255  IGTYGYMYRDIQMIRAIMYLAMILVIGVACFNIVSTLVMAVKDKSGDIAVLRTLGAKDGLIRAIFVWYGL  324 
V.cholerae LolE   255  QQKYGFLYRDIQLVRTIMYLVMVLVIGVASFNIVSTLMMAVKDRAGEIAILRTMGATDGLIKRIFVWQGV  324  
Y.pestis LolE     257  IGTYGYMYRDIQMIRTIMYLAMVLVIGVASFNIVSTLVMAVKDKSSDIAVLRTLGAKDGLIRAIFIWYGL  326 
H.influenzae LolE 257  ISKFGYMYRDIQLIRTVMYIAMVLVIGVACFNIVSTLIMAVKDKQGDIAIMRTLGANNAFIKRIFIWYGL  326 
P.aeruginosa LolE 255  TRTQGSLFNAMKMEKTMIGLLLLLIIAVAAFNIIATLIMVVADKRTDIAILRTLGATPRQIMAIFMVQGT  324  
 
A.baumannii LolF  224  TYTHGNLFNAIQMEKTLVGLLLVLIIVVAAFNIVSSLVMVVTDKKSDIAILRTLGASPSMITKIFMVQGT  293 
C.burnetii LolF   255  TEQFGSFFKAIAMEKTIMFVILLLIVGVAIFNLVSTLVMVVNDKRADIAILRTLGASPRTIMSIFVIQGA  324  
L.pneumo LolF     256  TQQFGAFFEAVKMEKTMMFMILLLIIAVAAFNLVSSLVMVVNDKQAEIAILRTIGATPSTILWVFIVQGM  325 
F.tularensis LolF 261  TDENKSFFDALKMEKTMMFFILLLIITVAVFNLLSSLVMVVTDKRSDIAILRTMGMSSRQIITVFIYQGF  330  
B.pseudo LolF     258  TQQNKTWFSAVQIEKRMMFIILTLIIAVAAFNLVSSLVMTVTNKQADIAILRTLGAQPGSIMKIFVVQGV  327  
N.menin LolF      256  TFSNRSYFEAVELEKRMMFIILTLIIAVAAFNLVSSLVMAVTEKQADIAILRTLGLSPGGVMKIFMVQGA  325  
H.pylori LolF     259  WQQNGNFFSAMELEKRALFIVLMLIILMASLNIISSLLMVVMNRRKEIALLFSMGSSQKEIQKTFFYLGN  328  
G.sulfur LolF     264  MQMNKNILFALKTEKMVMFIILTLIVLVAAFGIASTLFMVVMEKTKDIAILKSMGATGRSIMKIFVLEGL  333  
 
Consensus aa:          ......hhpshphbp.hh.hlhhl.l.Vtthslhs.hhhsV.-+p.-ltl..hhGhp...I...Fhhpth  
Consensus ss:          hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh    hhhhhhhhhhhhh    
 
Conservation:            5  8   8  56             5               5   5              7  5   5  
E.coli AatP       310  IMLSVCLFISII-------HAGVIMHIIKYFLDVKIS------IRTTMITISLAYVLLVFISA---NIIF  363  
A.actino MacB     574  LICLIGGVAGILLSVLIGVLFNSFIT-------------------DFSMDFSTASIVTAVLFSTLIGVLF  594  
E.coli MacB       578  LVCLVGGALGITLSLLIAFTLQLFLP-------------------GWEIGFSPLALLLAFLCSTVTGILF  628 
V.cholerae MacB   582  LVCLCGGAIGIGVAYLIGGLFATLGS-------------------SFSMIYSTTSIISAFLCSTLIGVLF  632  
N.gonor MacB      574  LICIIGGLVGVGLSAAVSLVFNHFVT-------------------DFPMDISAASVIGAVACSTGIGIAF  624  
C.jejuni  MacB    571  MICTIGAILGVILSIFVIFAFNTLST-------------------DFPMILNAYSVLLGLLSSMFIGVVF  621 
P.aeruginosa PvdT 595  MLSVVGGLAGIALALCIGGVLLLGQ---------------------VAVAFSLSAIVGAFSCALVTGLVF  643  
 
E.coli LolC       320  SAGIIGAILGAALGALLASQLNNLMPIIGVLL----------DGAALPVAIEPLQVIVIALVAMAIALLS  379 
S.enterica LolC   357  SAGIIGALLGAALGALLASQLNNLMPIIGAFL----------DGAALPVAIEPLQVIVIALVAMAIALLS  416 
V.cholerae LolC   325  SSGVIGALVGGLLGVLLAANLNSLMEALGVALFS--------VGGSLPVAIDPLQIVLVIVLAIVLSLLA  386  
Y.pestis LolC     321  TAGVIGALLGAGLGVLLASQLNTLIPILGVLI----------DGATLPVEIDPLQVTVIALLAMVIALLS  380 
H.influenzae LolC 316  LVGFVGTLLGAILGVLATLNLTDIVSAVNP------------QGVFLPTELSFVQMIFVIGFSLLLSLLS  373 
P.aeruginosa LolC 327  VIGVIGTLVGGVLGVVAALNVSAWISALEKLLGHQFLASDVYFIDYLPSQLMLDDVVLVCGAALVLSFFA  396  
 
E.coli LolE       325  LAGLFGSLCGVIIGVVVSLQLTPIIEWIEKLIGHQFLSSDIYFIDFLPSELHWLDVFYVLVTALLLS-LA  393 
S.enterica LolE   325  LAGLLGSLIGVAIGVVVSLQLTAIINGIEKAIGHQFLSGDIYFIDFLPSELHWLDVVYVLVTALLLSLLA  394 
V.cholerae LolE   325  FSGVLGSVVGSVLGMVVAFNLTPLIKGLEHLIGHQFLSGDIYFVDFLPSQVEWADVVLVSGTAIVLSLLA  394  
Y.pestis LolE     327  LAGLIGSISGAVIGVIVSLQLTTIIRGLEKMVGHQFLSSDIYFIDFLPSELRWFDVACVLATALVLSLIA  396 
H.influenzae LolE 327  QAGMKGCLIGIVLGIILALNLTTFIQGIEWVIGKKLLSGDVYFVDFLPSELHWLDVLMVLVAALALSLMA  396 
P.aeruginosa LolE 325  VIGVIGTVIGGVLGVFAALNITGMIDRIERLVGHKVFSSDVYFINYLPSDLQVLDVVLICSAALLMSFLA  394  
 
A.baumannii LolF  294  VIGVIGTVAGTVLGVILALTISDIISWFNNVLGLNLF--DAYFVHYLPSYLRWQDVTIIVIVSLLLSFLA  361 
C.burnetii LolF   325  IVGIVGTLIGVIGGVILAVNATAIVNGIQQIFHVQFLKSSIYFVNFLPSRLQWLDVLNVSLIAFALSLIA  394  
L.pneumo LolF     326  MVGLVGTILGLLGGLVLANNATEIVNALQSFFQVKVLSSSIYFVDYLPSKIMFRDLWQVCAMALLMSFAA  395 
F.tularensis LolF 331  IIGLIGTVIGVLLGILLSTYATEIVNFIQNLTGKQFLSASVYLINYIPSELMWSDVIKVTLVSMFLSFLA  400  
B.pseudo LolF     328  TIGFVGTATGVALGCLIAWSIPWLIPMIEHAFGVQFLPPSVYFISELPSELVAGDVIKIGVIAFALSALA  397  
N.menin LolF      326  FSGFFGTLAGVVCGVLLGWNVGRVVAFFENLLGVHLINSQVYFIDYLPSDVDMGDVALIACISLGLSFVA  395  
H.pylori LolF     329  IIGLGGVA----LGVVLAF----LSMYLLSVFPIISLPADVYGINTLPLNLSLMDFTLTLIGSVIIVGLS  390  
G.sulfur LolF     334  IIGISGTAIGVIGGLLVALNLEPIVGVIQRVTGFELFSKDVYYLDHFPSQVVPSDVLLISVTAVIISLVA  403  
 
Consensus aa:          hhthhGshhGhhlthllt..hs.h...l................s.hs..lph.plh.hhh.thhlthlh  
Consensus ss:          hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh                  ee hhhhhhhhhhhhhhhhhh    
 
Conservation:          5 597  76   75 68       
E.coli AatP       364  G----RLFFSINPVNAIKGKIE  381  
A.actino MacB     594  GYMPAKKAAELNPITALAQE--  644  
E.coli MacB       629  GWLPARNAARLDPVDALARE--  648 
V.cholerae. MacB  633  GYLPAKNAAQLNPIDALARE--  652  
N.gonor MacB      625  GFMPANKAAKLNPIDALAQD--  644  
C.jejuni  MacB    622  GFFPARNAANLNPISALSKE--  641  
P.aeruginosa PvdT 644  GFMPARKAAQLDPVAALASQ--  663  
 
E.coli LolC       380  TLYPSWRAAATQPAEALRYE--  399  
S.enterica LolC   417  TLYPSWRAAATQPAEALRYE--  436  
V.cholerae LolC   387  TLFPAYRASSVQPAEALRYE--  406  
Y.pestis LolC     381  TLYPSWRAAAAQPAEALRYE--  400  
H.influenzae LolC 374  TLYPAYRAAKVEPAAALRYE--  393  
P.aeruginosa LolC 397  TLYPAWRAARTQPAEALRYE--  416  
 
E.coli LolE       394  SWYPARRASNIDPARVLSGQ--  413  
S.enterica LolE   395  SWYPARRASNIDPARVLSGQ--  414  
V.cholerae LolE   395  TWYPARRASRLNPAQVLSSK--  414  
Y.pestis LolE     397  SWYPARRASRIDPARVLSGQ--  416  
H.influenzae LolE 397  SLYPASRAAKLQPAQVLSSH--  416  
P.aeruginosa LolE 395  TLYPSWRAARTQPAESLRYE--  414  
 
A.baumannii LolF  362  TIYPALRAAKVQPAEALRYE--  381  
C.burnetii LolF   395  TIYPAFIAFRTEPAEALRYE--  414  
L.pneumo LolF     396  TIYPAWRASKTVIAEALHYE--  415  
F.tularensis LolF 401  TLYPAWSASKVQPVEALRYE--  420  
B.pseudo LolF     398  TLYPSWRGAKVRPAEALRYE--  417  
N.menin LolF      396  TLYPSRRASKTQPAEALRYE--  415  
H.pylori LolF     391  SYYPSKKASTIDALSVLRNE--  410  
G.sulfur LolF     404  TLYPSWQASRLPPAEALRYE--  423  
 
Consensus aa:          shhPt.pAtphpPhphL..c..  
Consensus ss:          hhhhhhhhh   hhhhh         
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Figure S4. Protein alignment of members of the MacB superfamily. Sequence alignment was 
generated with Promals3D excluding the nucleotide-binding domain of MacB and PvdT. Sequences 
corresponding to predicted helices are highlighted in red, β-sheets in blue. Abbreviations are as follows 
E.coli, Escherichia coli; A.actino, Aggregatibacter actinomycetemcomitans; V.cholerae, Vibrio 
cholerae; N.gonor, Neisseria gonorrhoeae ; C.jejuni, Campylobacter jejuni; P.aeruginosa, 
Pseudomonas aeruginosa; S.enterica, Salmonella enterica serovar Typhimurium; Y.pestis, Yersinia 
pestis; H.influenzae, Haemophilus influenzae; A.baumannii, Acinetobacter baumannii; C.burnetii, 
Coxiella burnetii; L.pneumo, Legionella pneumophila; F.tularensis, Francisella tularensis; B.pseudo, 
Burkholderia pseudomallei; N.menin, Neisseria meningitidis; H.pylori, Helicobacter pylori; G.sulfur, 
Geobacter sulfurreducens. 
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Figure S5. LolA does not bind to the LolE periplasmic domain. (A) Size-exclusion chromatography 
profiles for LolA, LolE periplasmic domain and a mixture of the two proteins. (B) Isothermal titration 
calorimetry using LolE and LolA. Both experiments were performed under conditions where LolC and 
LolA interact with high affinity. 
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Figure S6. LolB does not interact with LolC. (A) Size-exclusion chromatography experiment for 
LolB, LolC periplasmic domain and a mixture of the two proteins. (B) Assessment of the in vitro 
interaction of LolC with LolA or LolB. Untagged LolC periplasmic domain was added to His-tagged 
LolA (A+C) or LolB (B+C) immobilized on IMAC resin. After washing, bound proteins were eluted 
with imidazole and analysed on SDS-PAGE. Purified LolC periplasmic domain, C; LolA, A; and LolB, 
B are loaded as a reference. Molecular weights of protein standards (M) are indicated. (C) Comparison 
of LolA (6F3Z) and LolB (1IWM) showing the presence of an extra loop in LolA (dark surface). (D) 
Sequence alignment of LolA and LolB proteins showing the C-terminal region. Secondary structural 
elements of LolA are indicated above the sequence alignment. Residues in E. coli LolA that interact 
with the LolC Pad are highlighted in red. Abbreviations are as follows Ec, Escherichia coli; Vc, Vibrio 
cholerae; St, Salmonella enterica serovar Typhi; Pa, Pseudomonas aeruginosa; Ab, Acinetobacter 
baumannii. 
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Figure S7. LolA-binding and ATPase assays for wild-type and variant LolCDE complexes. (A) In 
vitro interaction of LolA with wild-type LolCDE (left) or LolCD(E171Q)E variant (right) in the 
presence and absence of ATP or ATPγS. Wild-type LolCDE or E171Q variant bearing a His-tag on 
LolD were incubated with no nucleotide (-), 1 mM ATP or ATPγS as indicated, and immobilized on 
IMAC resin. Untagged LolA was then added, the resin washed, and bound proteins eluted with 
imidazole and analysed on SDS-PAGE. Purified proteins loaded as references are LolCDE, CDE; and 
LolA, A. Molecular weights of protein standards (M) are indicated. (B) In vitro interaction of LolA with 
wild-type LolCDE untreated or treated with 5 mM EDTA. (C) ATPase assays for wild-type LolCDE in 
the absence and presence of 5 µM LolA. Results correspond to the mean ± standard deviation for 
triplicate determinations. (D) Assessment of the in vitro interaction of LolA with wild-type or variant 
LolCDE. LolA binding assay in the absence of nucleotide for wild-type LolCDE and indicated variants: 
ΔHook, R163A, M175R, correspond to mutations in LolC component of LolCDE; ΔE Hook 
corresponds to LolCDE with the Hook removed from LolE. (E) ATPase assays for wild-type and variant 
LolCDE complexes. Results correspond to the mean ± standard deviation for triplicate determinations.  
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Figure S8. LolCDE inhibitor Compound 2 stimulates ATPase activity but does not interfere with 
LolA binding. (A) ATPase assay for wild-type LolCDE in the presence of 0, 10 or 100 µM Compound 
2. ATP hydrolysis rates correspond to the mean ± standard deviation for triplicate determinations. (B) 
Effect of Compound 2 on the in vitro interaction of LolC and LolA. His-tagged LolC periplasmic domain 
was incubated with the indicated concentration (µM) of Compound 2 and immobilized on IMAC resin 
prior to the addition of untagged LolA. After washing, bound proteins were eluted with imidazole and 
analysed on SDS-PAGE. Purified LolC periplasmic domain, C; and LolA, A are loaded as a reference. 
Molecular weights of protein standards (M) are indicated. (C) Effect of Compound 2 on the in vitro 
interaction of His-tagged LolCDE and LolA. 
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Figure S9. Additional electron density in the LolA·LolC structure suggestive of indole. (A, B) Sites 
within the asymmetric unit with additional difference map electron density suggestive of indole. The 
difference electron density map is shown as a blue mesh contoured at 3 σ. (C) Locations of putative 
indole sites within the context of the asymmetric unit. The presence of indole was biochemically 
confirmed for the E. coli culture used to express these proteins, but not for the protein solution. We 
therefore chose to omit indole from the deposited coordinates while highlighting its possible presence 
here.  
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Supplemental Tables 
 
 
Table S1. X-ray data and refinement statistics  
 LolA bound to LolC 
periplasmic domain LolC ∆Hook  LolA F47E  
    
PDB code 6F3Z 6F49 6FHM 
    
Data Collection    
Beamline ESRF 30B ESRF 30B Diamond I03 
Wavelength (Å) 0.9763 0.9763 0.9763 
    
Crystal Parameters    
Space Group P21 21 2 P21 21 21 P2 21 21 
Unit Cell Dimensions (Å) 146.0, 68.2, 94.8 75.3, 108.5, 109.5 61.0, 77.6, 103.6 
Unit Cell Angles (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Mosaic Spread (°) 0.58 0.58 0.44 
    
Reflection Data     
Resolution Range (Å) 73.01-2.00 (2.05-2.00) 62.04-2.02 (2.07-2.02) 62.11-2.39 (2.48-2.39) 
Unique Reflections 61745 (4379) 58914 (4321) 20165 (2087) 
Rsym 0.103 (0.844) 0.166 (0.684) 0.196 (1.167) 
I/σ(I) 10.6 (2.2) 6.7 (2.0) 6.7 (2.1) 
CC½  0.997 (0.883) 0.990 (0.704) 0.984 (0.893) 
Completeness (%) 95.8 (97.0) 99.1 (99.5) 100.0 (100.0) 
Multiplicity 10.2 (9.9) 5.0 (5.2) 11.4 (11.8) 
Wilson B (Å2) 33.5 14.1 47.2 
    
Refinement     
Resolution (Å) 73.01 (2.00) 62.04 (2.02) 62.11 (2.39) 
Number of Reflections 58544 55872 19110 
Rwork 0.2022 0.1884 0.2147 
Rfree 0.2492 0.2328 0.2693 
Rms (Bond Lengths) (Å) 0.019 0.015 0.015 
Rms (Bond Angles) (°) 1.85 1.70 1.67 
    
Model Composition    
Protein atoms 6536 6639 2987 
Waters 152 452 48 
Other 0 84 18 
    
Model B-factors    
Protein atoms (Å2) 47.1 22.9 61.4 
Waters (Å2) 42.6 26.9 54.1 
Other - 39.1 68.6 
    
Ramachandran Statistics     
Favoured (%) 97.0 99.0 95.5 
Allowed (%) 3.0 1.0 4.5 
Outliers (%) 0.0 0.0 0.0 
    
Values in parentheses indicate the outer resolution bin. 
Reflection data is as reported by Aimless (52). 
Refinement statistics as reported by Refmac (55). 
Ramachandran statistics from Rampage (56). 
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Table S2. ITC data for LolA binding by LolC periplasmic domain variants 
 
 Kd (µM) N ΔG ΔH -TΔS 
      
LolC 
0.3, 0.4, 
0.4, 0.5 
0.4 ± 0.1 
1.02, 0.92, 
0.91, 1.21 
1.01 ± 0.14 
-8.9, -8.7, 
-8.7, -8.6 
-8.7 ± 0.1 
7.0, 7.7, 
8.3, 6.2 
7.3 ± 0.9 
-15.9, -16.4, 
-17.0, -14.8 
-16.0 ± 0.9 
      
LolC ΔHook No binding - - - - 
      
LolC R163A No binding - - - - 
      
LolC Q171A 0.4, 0.5 0.4 ± 0.1 
0.97, 0.99 
0.98 ± 0.01 
-8.7, -8.6 
-8.7 ± 0.1 
7.1, 7.0 
7.0 ± 0.1 
-15.8, -15.6 
-15.7 ± 0.1 
      
LolC F172A 4.0, 3.6 3.8 ± 0.3 
1.02, 1.04 
1.03 ± 0.01 
-7.4, -7.4 
-7.4 ± 0.0 
8.5, 7.6 
8.0 ± 0.6 
-15.8, -15.0 
-15.4 ± 0.6 
      
LolC T173A 62.5, 74.3, 71.9 69.6 ± 6 1.00 * 
-5.7, -5.6, -5.6 
-5.7 ± 0.1 
8.5, 8.0, 6.4 
7.6 ± 1.1 
-14.2, -13.6, -12.1 
-13.3 ±1.1 
      
LolC M175A 4.9, 4.0 4.5 ± 0.6 
1.03, 1.03 
1.03 ± 0.00 
-7.2, -7.4 
-7.3 ± 0.1 
11.9, 9.8 
10.8 ± 1.5 
-19.2, -17.1 
-18.1 ± 1.4 
      
LolC R177A 2.5, 1.7 2.1 ± 0.5 
0.87, 0.92 
0.90 ± 0.04 
-7.6, -7.8 
-7.7 ± 0.2 
-7.2, -7.4 
7.3 ±0.1 
-15.4, -14.8 
-15.1 ± 0.4 
      
LolC I178A 12.7, 10.0 11.4 ± 1.9 
0.93, 1.11 
1.02 ± 0.13 
-6.7, -6.8 
-6.7 ± 0.1 
6.1, 6.1 
6.1 ± 0.0 
-12.8, -12.9 
-12.9 ± 0.1 
      
LolC Q181A 1.6, 1.4 1.5 ± 0.1 
1.06, 1.09 
1.07 ± 0.02 
-7.9, -8.0 
7.1 ± 0.0 
7.3, 6.9 
7.1 ± 0.3 
15.2, -14.9 
-15.1 ± 0.3 
      
LolC R182A 26.3, 36.2 31.2 ± 7.0 1.00 * 
-6.2, -6.1 
3.6 ± 0.1 
3.4, 3.8 
3.6 ± 0.3 
-9.7, -9.9 
-9.8 ± 0.1 
      
LolC F172R 8.4, 3.7 6.1 ± 3.3 
1.07, 1.08 
1.08 ± 0.01 
-6.9, -7.4 
6.8 ± 0.3 
7.7, 5.8 
6.8 ± 1.4 
14.7, -13.2 
-13.9 ± 1.0 
      
LolC M175R No binding - - - - 
      
 
Mean ± standard deviation in bold. ΔG, ΔH and TΔS reported in kcal mol-1. T=25 °C. 
* Stoichiometry was fixed at 1:1 for LolA binding by the T173A and R182A LolC variants. 
Fits and thermograms in Figure S2. 
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Table S3. Correlation between in vivo crosslinking data and the LolA·LolC crystal structure. 
 
Photo-crosslinker 
substitution in LolA 
Crosslink to 
LolC? 
Nearest LolC* 
residue  Distance (Å) 
    
F20  P174 6.50 
V24 + F172 4.06 
Q33 + F172 2.65 
W40  P174 9.70 
R43   - 
D55 + R213 4.82 
L59 + T173 3.60 
K64  M175 9.26 
F72 + R210 3.11 
S99   - 
V114   - 
K118   - 
F127   - 
R133   - 
E144 + F172 5.19 
R149  F172 7.57 
K155   - 
A165   - 
Q173  R182 9.72 
T176 + R182 3.23 
Q180  Q181 3.01 
    
 
*Nearest neighbour located more than 10 Å away are not reported. 
Distance measurements are for chains A and B in the LolA·LolC crystal structure (6F3Z). 
Columns 1 and 2 from Tokuda (27), columns 3 and 4 this work. 
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Table S4. List of primers for PCR amplification.  	
Primers Description Sequence (5’ to 3’) 
P1 LolA_NheI_F GCGCGCTAGCATGGATGCCGCAAGCGATCTGAAAAGC 
P2 LolA_BamHI_R GCGCGGATCCTTACTACTTACGTTGATCATCTACCGTGACGCC  
P3 Soluble LolB_NdeI_F GCGCCATATGTCCGTTACCACGCCCAAAGGTCCTG  
P4 Soluble LolB_BamHI_R GCGCGGATCCTTATTTCACTATCCAGTTATCCATTTTTAAC 
P5 periLolC_NdeI_F GCGCCATATGAACGGCTTTGAGCGCGAGCTG  
P6 periLolC_BamHI_R GCGCGGATCCTTACATATTTTTTTCCATGCGTACGGCCTG 
P7 periLolC ∆Hook_R GAACAGGCGCTGGCTCGCACCTACCATCACGCGGATTTGATC 
P8 periLolC_NotI_R GCGCGCGGCCGCCATATTTTTTTCCATGCGTACGGCCTG 
P9 periLolC ∆Hook_F GATCAAATCCGCGTGATGGTAGGTGCGAGCCAGCGCCTGTTC 
P10 periLolE_NdeI_F GCGCCATATGCATGGTGAAATCGAGGCG 
P11 periLolE_XhoI_R GCGCCTCGAGCCAGCTTTTAATATAAACATAGCTGTTGGTCAC 
P12 periLolE ∆Hook_R GCAAACGCACACGTTTCGCACCGATCATAATCGACACCC 
P13 periLolE ∆Hook_F GGGTGTCGATTATGATCGGTGCGAAACGTGTGCGTTTGC 
P14 periLolC_F_BspHI GCGCTCATGAAATACCTGCTGCCGACCGCTGC  
P15 T7_F TAATACGACTCACTATAGGG 
P16 His-tag_R_HindIII GCGCAAGCTTTTAGTGGTGGTGGTGGTGGTGCTCG 
P17 LolCD_PciI_F GCGCACATGTACCAACCTGTCGCTCTATTTATTGGCCTGCGTTACATG 
P18 LolCD_NotI_R GCGCGCGGCCGCTTAGTGGTGGTGGTGGTGGTGAGAACCCTCCGCCCCCATCAGGCTCAGTTCCGC 
P19 LolE_NdeI_F GCGCCATATGGCGATGCCTTTATCGTTATTAATTGGCCTG 
P20 LolE_AvrII_R GCGCCCTAGGTTACTGGCCGCTAAGGACTCGCGCAGG 
P21 LolA F74E_F GTTGTGTCATATGCCAGTTCTCTAAGTTTGGACGTTTCACCCACAG 
P22 LolA F74E_R CTGTGGGTGAAACGTCCAAACTTAGAGAACTGGCATATGACACAAC 
P23 periLolC R163A_F CGTTAATCGCGGTGATCAAATCGCGGTGATGGTACCATCTGCC 
P24 periLolC R163A_R GGCAGATGGTACCATCACCGCGATTTGATCACCGCGATTAACG 
P25 periLolC Q171A_F CGTGATGGTACCATCTGCCAGCGCGTTCACGCCGATGGGGCG 
P26 periLolC Q171A_R CGCCCCATCGGCGTGAACGCGCTGGCAGATGGTACCATCACG 
P27 periLolC F172A_F GGTACCATCTGCCAGCCAGGCGACGCCGATGGGGCGTATTCC 
P28 periLolC F172A_R GGAATACGCCCCATCGGCGTCGCCTGGCTGGCAGATGGTACC 
P29 periLolC F172R_F GGTACCATCTGCCAGCCAGCGCACGCCGATGGGGCGTATTCC 
P30 periLolC F172R_R GGAATACGCCCCATCGGCGTGCGCTGGCTGGCAGATGGTACC 
P31 periLolC T173A_F CCATCTGCCAGCCAGTTCGCGCCGATGGGGCGTATTCC 
P32 periLolC T173A_R GGAATACGCCCCATCGGCGCGAACTGGCTGGCAGATGG 
P33 periLolC M175A_F GCCAGCCAGTTCACGCCGGCGGGGCGTATTCCAAGCCAGC 
P34 periLolC M175A_R GCTGGCTTGGAATACGCCCCGCCGGCGTGAACTGGCTGGC 
P35 periLolC M175R_F GCCAGCCAGTTCACGCCGCGCGGGCGTATTCCAAGCCAGC 
P36 periLolC M175R_R GCTGGCTTGGAATACGCCCGCGCGGCGTGAACTGGCTGGC 
P37 periLolC R177A_F GCCAGTTCACGCCGATGGGGGCGATTCCAAGCCAGCGCCTG 
P38 periLolC R177A_R CAGGCGCTGGCTTGGAATCGCCCCCATCGGCGTGAACTGGC 
P39 periLolC I178A_F GTTCACGCCGATGGGGCGTGCGCCAAGCCAGCGCCTGTTC 
P40 periLolC I178A_R GAACAGGCGCTGGCTTGGCGCACGCCCCATCGGCGTGAAC 
P41 periLolC Q181A_F CGATGGGGCGTATTCCAAGCGCGCGCCTGTTCAATGTGATTGG 
P42 periLolC Q181A_R CCAATCACATTGAACAGGCGCGCGCTTGGAATACGCCCCATCG 
P43 periLolC R182A_F GGGCGTATTCCAAGCCAGGCGCTGTTCAATGTGATTGGC 
P44 periLolC R182A_R GCCAATCACATTGAACAGCGCCTGGCTTGGAATACGCCC 
P45 LolD E171Q_F CCTGGTACTGGCGGATCAGCCTACCGGTAACC 
P46 LolD E171Q_R GGTTACCGGTAGGCTGATCCGCCAGTACCAGG 
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Table S5. List of plasmid constructs used in this study. 
 
Name Description Reference 
pET28a Expression vector Novagen 
pET24a Expression vector Novagen 
pET26b Vector encoding pelB signal sequence Novagen 
pETDuet-1 Expression vector Novagen 
pET28-LolA Expresses LolA (residues 22-203) with an N-terminal His-tag This study 
pET24-LolA Expresses LolA (residues 22-203) with a C-terminal His-tag This study 
pET28-mLolB Expresses mLolB (residues 23-207) with an N-terminal His-tag This study 
pET28-LolA(F47E) Expresses LolA F47E (residues 22-203) with an N-terminal His-tag This study 
pET24-periLolC  Expresses LolC (residues 48-266) with a C-terminal His-tag (33) 
pET28-periLolC  Expresses LolC (residues 48-266) with an N-terminal His-tag This study 
pET24-periLolC(∆Hook) Expresses LolC (residues 48-266) with a C-terminal His-tag. Residues 167-179 replaced by a GA linker This study 
pET24-periLolC(XnY) Expresses LolC (residues 48-266) with a C-terminal His-tag, residue X at position n mutated to residue Y  This study 
pET24-periLolE  Expresses LolE (residues 65-254) with a C-terminal His-tag This study 
pET24-periLolE(∆Hook) Expresses LolE (residues 65-254) with a C-terminal His-tag. Residues 171-182 replaced by a GA linker This study 
pETDuet-LolCDE lolCD cloned in the first MCS of pETDuet-1 with a C-terminal His-tag on lolD, lolE cloned in the 2nd MCS This study 
pETDuet-LolC(R163A)DE Expresses LolCDE with an R163A variant of LolC This study 
pETDuet-LolC(M175R)DE Expresses LolCDE with an M175R variant of LolC This study 
pETDuet-LolCD(E171Q)E Expresses LolCDE with an E171Q variant of LolD This study 
pETDuet-LolC(∆Hook)DE Expresses LolCDE with residues 167-179 of LolC replaced by a GA linker This study 
pETDuet-LolCDE(∆Hook) Expresses LolCDE with residues 171-182 of LolE replaced by a GA linker This study 
pBAD18-pelBperiLolC  Expresses LolC (residues 48-266) with an N-terminal PelB signal peptide and a C-terminal His-tag This study 
pBAD18-
pelBperiLolC(∆Hook) 
Expresses LolC (residues 48-266) with an N-terminal PelB signal 
peptide and a C-terminal His-tag. Residues 167-179 replaced by a 
GA linker 
This study 
pBAD18-pelBperiLolC(XnY) 
Expresses LolC (residues 48-266) with an N-terminal PelB signal 
peptide and a C-terminal His-tag. Residue X at position n mutated 
to residue Y  
This study 	 	
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Supplemental Movies 
 
Movie 1. Roving camera tour of the LolA·LolC structure showing representative electron density. 
A weighted 2|Fo|-|Fc| electron density map, calculated with model phases, is shown as blue mesh 
contoured at 1 σ.  
 
Movie 2. Molecular morph showing conformational changes in LolA due to LolC binding. Left, 
cartoon structure of LolA alternating between its conformation in isolation (1IWL) and within the 
LolA·LolC complex (6F3Z). Right, the same morph using a surface representation of LolA (yellow) 
with the LolC Hook (teal). Orientations differ by a quarter turn about the horizontal axis; on the left 
hand side, the mouth of LolA is located at the bottom of the frame, on the right hand side, it is viewed 
face-on. 
 
Movie 3. Electron density for the LolA F47E variant. One monomer is coloured in red, one in blue 
to demonstrate the strand exchange between the two monomers, within the domain-swapped dimer. The 
glutamate residues at position 47 are shown in yellow. A weighted 2|Fo|-|Fc| electron density map, 
calculated with model phases, is shown as blue mesh contoured at 1 σ.  
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Supplemental Methods 
 
Construction of strains and plasmids 
Details of the primer sequences and constructs used in this study appear in Tables S4 and S5 
respectively. For cytoplasmic expression of LolA, the mature domain of LolA (residues 22-203) lacking 
the N-terminal secretion signal was amplified from E. coli M1655 genomic DNA using primers P1/P2, 
digested NheI-BamHI, and inserted into pET28a (Novagen) digested with the same enzymes. The 
resultant vector, pET28-LolA, encodes N-terminal His-tagged mature LolA. Similarly, a plasmid 
expressing the mature domain of LolB (residues 23-207) with an N-terminal His-tag was amplified with 
primers P3/P4, digested NdeI-BamHI and ligated into pET28a resulting in pET28-mLolB. pET28-
periLolC encoding LolC periplasmic domain (residues 48-266) with an N-terminal thrombin-cleavable 
His-tag was created by amplification with P5/P6, digestion with NdeI/BamHI and ligation into pET28a 
digested with the same enzymes. pET24-periLolC encoding the C-terminally His-tagged periplasmic 
domain of LolC was previously described (33). Residues 167-179 inclusive were replaced by a Gly-Ala 
linker by two-step PCR using primers P5/P7 and P8/P9. A mixture of these reactions served as a 
template for a final reaction with P5/P8. Digestion of this product with NdeI-NotI and introduction into 
NdeI-NotI digested pET24a resulted in pET24-periLolC(ΔHook). The extent of the periplasmic region 
of LolE (residues 65-254) was determined using the periLolC structure (5NAA) as a guide and amplified 
from MG1655 E. coli genomic DNA using the primers P10/P11. After digestion by NdeI and XhoI, 
PCR products were ligated into pET24a digested with the same enzymes, resulting in pET24-periLolE. 
The periLolE Hook was removed in a similar manner to that described for periLolC using two stages of 
PCR P10/P12 and P11/P13 and then an amplification of a mixture of the products with P10/P11. The 
resultant fragment was digested and ligated into pET24. The resultant plasmid, pET24-
periLolE(ΔHook) encodes periLolE with residues 171-182 inclusive replaced by a Gly-Ala linker. Point 
mutations of LolA or periLolC were created by Quikchange site-directed mutagenesis from pET28-
LolA or pET24-periLolC respectively using the primers listed in Table S4. 
 
To target the periplasmic domain of LolC (wild-type or variant) to the periplasm, the region 
corresponding to residues 48-266 was amplified with primers P8/P14, digested BspHI-NotI and cloned 
into NcoI-NotI digested pET26b (Novagen). The entire region comprising periLolC with an N-terminal 
pelB secretion signal and C-terminal His-tag was then amplified with primers P15/P16, digested Xba-
HindIII and introduced into pBAD18 (59) resulting in plasmid pBAD18-pelBperiLolC or indicated 
variant. 
 
To express E. coli LolCDE with a His-tag on the C-terminus of LolD, the lolCD contiguous region was 
amplified with primers P17/P18 digested with PciI and NotI, and cloned into the first MCS (Multiple 
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Cloning Site) of pETDuet digested with the same enzymes. lolE was amplified with primers P19 and 
P20, digested NdeI-AvrII and introduced into the second MCS of the resulting plasmid to create 
pETDuet-LolCDE. Variants in LolCDE were created by a two-step PCR using mutagenic internal 
primers and P17/P18 or P19/P20 with pETDuet-LolCDE as template. After restriction enzyme digest, 
the variant lolCD or lolE PCR products were ligated into pETDuet-LolCDE from which the wild-type 
copies of lolCD or lolE had been excised. All clones were verified by DNA sequencing (Source 
BioScience).  
 
Protein purification 
 
Purification of wild-type and variant E. coli LolCDE 
E. coli C43 (DE3) (58) carrying pETDuet-LolCDE or variants: LolC(R163A)DE, LolC(M175R)DE, 
LolC(E171Q)DE, LolC(∆Hook)DE, LolCDE(∆Hook) were grown in 2YT media supplemented with 
100 µg/mL carbenicillin for 16h at 30 °C. Cells were pelleted at 3500 g for 15 min, resuspended in fresh 
media and protein expression induced with 1 mM IPTG. After 2.5 hours of induction at 30 °C, cells 
were harvested by centrifugation at 6000 g for 6 min and pellets frozen at -80 °C. Bacterial pellets were 
thawed at room temperature and resuspended in buffer composed of 50 mM Tris pH 7.5, 150 mM NaCl 
and 10 % (v/v) glycerol. Cells were then lysed by passage through a Constant Systems cell disruptor at 
30200 psi. Unbroken cells and debris were removed by centrifugation at 10000 g for 10 min. Membranes 
were recovered from the supernatant by centrifugation at 115000 g at 5 °C for 2h and resuspended in 
the same buffer containing 1 % (w/v) DDM (dodecyl maltopyranoside) for solubilisation. After 1h, the 
soluble fraction was recovered by centrifugation (1h at 115000 g, 5 °C), supplemented with 40 mM 
imidazole and loaded on IMAC resin (Biorad Profinity) for 1h. The resin was washed with 50 mM Tris 
pH 7.5, 150 mM NaCl, 10 % (v/v) glycerol, 0.03 % DDM and 40 mM imidazole and the protein eluted 
with the same buffer containing 500 mM imidazole. Eluted LolCDE complex was buffer exchanged 
into 20 mM HEPES pH 7.5, 150 mM NaCl, 0.03 % DDM using either PD10 columns (GE Healthcare) 
or Amicon Ultra 100 kDa cut-off centrifugal concentrators and concentrated using the same device to 
5-10 mg/mL before flash freezing and storage at -80 °C.  
 
Purification of wild-type and variant E. coli LolC periplasmic domain  
E. coli BL21 (DE3) cells bearing plasmid pET24-periLolC or pET24-periLolC(XnY) variant were 
grown in 1L of 2YT medium supplemented with 50 µg/mL kanamycin at 30 ºC. When the culture 
achieved an OD600 of 0.8 the temperature was reduced to 18 ºC and protein expression induced with 0.1 
mM IPTG. After 16h further growth, cells were harvested by centrifugation at 4000 g and the pellet 
resuspended in 50 mL of 50 mM HEPES pH 7.5, 300 mM NaCl, supplemented with protease inhibitor 
cocktail (Roche), lysozyme and DNase. Bacteria were lysed by cell disruption (Constant Systems) at 
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30200 psi before removal of bacterial debris by ultracentrifugation (1h, 115000 g at 5 ºC). The soluble 
fraction was supplemented with 20 mM imidazole and loaded on to a 5 mL HisTrap FF column using 
an ÄKTAxpress FPLC (GE Healthcare). Bound proteins were washed with 15 column volumes (CV) 
of the same buffer, before elution with 250 mM imidazole. Peak fractions were analysed on SDS-PAGE 
and pooled according to purity in a 10 kDa exclusion size centricon filter (Amicon). Proteins were buffer 
exchanged into 20 mM HEPES pH 7.5, 150 mM NaCl using a 10 kDa cut-off centricon device (Amicon) 
and concentrated to 20-30 mg/mL, before flash freezing and storage at -80 °C. When required the C-
terminal His-tag was removed using the Thrombin CleanCleave Kit (Sigma) according to the 
manufacturer’s instructions. 
 
Purification of E. coli wild-type and variant LolE periplasmic domain 
The periplasmic domain of LolE and equivalent ∆Hook variant were produced and purified as described 
for LolC with a purification buffer composed of 50 mM Tris pH 8.0, 300 mM NaCl and 10 % (v/v) 
glycerol and a desalting buffer comprising 20 mM HEPES pH 7.5, 150 mM NaCl and 5 % (v/v) glycerol. 
Proteins were stored at -80 °C at 15 mg/mL. 
 
Purification of E. coli wild-type LolA and LolA F47E 
Wild-type and LolA F47E proteins were produced in E. coli BL21 (DE3) bearing pET28-LolA or 
pET28-LolA(F47E). Cells were grown at 37 °C in 1L of 2YT medium supplemented with 50 µg/mL 
kanamycin. Cultures were induced with 0.1 mM IPTG when an OD600 of 0.8 was reached and 
temperature was reduced to 18 °C. After 16h, bacteria were harvested by centrifugation at 4000 g and 
resuspended in a buffer composed of 50 mM Tris, pH 8.0, 300 mM NaCl before lysis in a cell disruptor 
(Constant Systems) at 30200 psi in the presence of lysozyme and DNase. Cell debris were removed by 
ultracentrifugation (1h, 115000 g at 5 ºC). The soluble fraction was supplemented with 20 mM 
imidazole and loaded onto a 5 mL HisTrap FF column using an ÄKTAxpress system (GE Healthcare). 
Bound proteins were washed with 15 CV of the same buffer, before elution with 250 mM imidazole. 
Peak fractions were analysed on SDS-PAGE and pooled in a 10 kDa cut-off centrifugal concentrator 
(Amicon). Proteins were then buffer exchanged into 20 mM HEPES at pH 8.0 and 200 mM NaCl and 
concentrated to 25 mg/mL. When required, the N-terminal His-tag was removed using the Thrombin 
CleanCleave Kit (Sigma) according to the manufacturer’s instructions. After cleavage, the protein was 
re-purified using Ni-IMAC to remove free His-tags and uncleaved His-tagged protein. 
 
Purification of E. coli wild-type soluble LolB 
Soluble LolB was produced in E. coli BL21 transformed with pET28-mLolB and purified as described 
for wild-type LolA with a buffer composed of 20 mM Tris pH 7.4, 150 mM NaCl and 0.25 mM TCEP. 
The protein was desalted with the same buffer containing no TCEP. Proteins were stored at -80 °C at 
30 mg/mL. 
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Size-exclusion chromatography analysis 
Size-Exclusion Chromatography (SEC) was performed on a Superdex 75, 10/300 GL column run at 0.8 
mL/min using an ÄKTA Pure FPLC system (GE Healthcare) equipped with a 100 µL injection loop. 
The running buffer was composed of 20 mM HEPES at pH 7.5, 150 mM NaCl. For analysis of individual 
proteins, 0.5 mg of protein was loaded onto the column. To assess the interaction of two proteins, 0.5 
mg of each protein was mixed and incubated for 5 minutes prior to injection.  
 
Isothermal titration calorimetry (ITC) 
ITC experiments were carried out at 25 °C in a VP-ITC calorimeter (MicroCal, GE Healthcare) by 
injecting 300 or 450 µM of wild-type or variant LolC periplasmic domain into 25 µM LolA. ITC buffer 
was composed of 20 mM HEPES pH 7.5, 200 mM NaCl. Initially 5 µL was injected over 10 s followed 
by injections of 10 µL over 20 s until the syringe was empty. Injections occurred every 200 s and the 
cell stirring speed was 300 rpm. To characterise the interaction of LolA and LolE, LolA (450 µM) was 
injected into the cell containing 25 µM periplasmic LolE while LolA F47E (200 µM) was injected into 
25 µM LolC periplasmic domain. For each titration, a control run with injectant and buffer alone in the 
cell was performed. The resulting signal was subtracted as a linear fit from protein-protein data. Binding 
affinity, stoichiometry and thermodynamic parameters were obtained by nonlinear least-squares fitting 
of experimental data using a single-site binding model from the Origin software package. 
  
Crystallization and structure determination 
All crystals were grown at 15 °C by the sitting drop vapour diffusion method over a reservoir of 80 µL 
in MRC 2-drop plates (Molecular Dimensions). 
 
LolA·LolC complex 
Individually purified LolC periplasmic domain and LolA were incubated together (both at a final 
concentration of 6 mg/mL) in 20 mM HEPES pH 7.5, 150 mM NaCl and then mixed with the 
precipitation solution at a 1:1 ratio in a final volume of 1 µL over a reservoir of 80 µL. Crystals of the 
LolA·LolC complex were obtained in 100 mM HEPES pH 6.5, 45 % (w/v) poly(acrylic acid sodium 
salt) 2100. Crystals were obtained after two days following seeding with crushed crystals of LolA F47E 
and LolC periplasmic domain obtained in 13-17 % PEG 8000, 10-20 % (v/v) glycerol and 30-60 mM 
KH2PO4. The cryoprotective solution was composed of the reservoir solution supplemented with 20 % 
ethylene glycol. Data were collected on beamline ID30B at ESRF. The structure was solved by 
molecular refinement with Phaser (53) using the wild-type LolC periplasmic domain (5NAA) after 
trimming residues 48-63, 170-179, 252-273 and LolA (1IWL) after removing loops corresponding to 
amino acids 115-124 and 180-182. Iterative cycles of density modification with Parrot (60) and 
automated model building with Buccaneer (61) produced a model that was further improved with several 
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rounds of Refmac (55) and manual building in Coot (54). Extra density present at the interface of LolA 
monomers was consistent with indole (Figure S9). Indole was positively identified in the growing 
bacterial culture using Kovac’s reagent but not in the protein solution, possibly due to insensitivity of 
the test. Consequently, indole was not included in the final coordinate file (PDB 6F3Z).  
 
LolA F47E mutant 
Crystals of LolA F47E protein were obtained by mixing 0.5 µL of protein at 12 mg/mL in 20 mM 
HEPES pH 7.5, 150 mM NaCl with the same volume of a precipitant solution composed of 13 % (w/v) 
PEG 8000, 20 % (v/v) glycerol. No seeding procedure was used. Crystals appeared after three days and 
were cryoprotected in the reservoir solution containing glycerol at a final concentration of 36 % (v/v) 
before being frozen in liquid nitrogen. X-ray diffraction data were obtained at Diamond (UK) on 
beamline I03 equipped with a Pilatus3 6M detector. LolA (1IWL) was used as a search model in Phaser 
(53) for molecular replacement after trimming residues 1-26, 32-51 and 88-161. After a round of 
refinement in Refmac (55), a new set of phases was generated by density modification using Parrot (60). 
The final model was obtained after a round of auto-building with Buccaneer (61), manual manipulation 
using Coot (54) and refinement with Refmac (55). 
 
LolC ∆Hook periplasmic domain 
LolC periplasmic domain lacking the Hook (∆167-179 GA) was crystallised similarly to LolA F47E 
with protein concentrated to 12 mg/mL and a precipitant solution composed of 30 % (w/v) PEG 2000 
MME, 150 mM sodium acetate pH 4.6, 200 mM ammonium sulfate. Seeds of wild-type LolC 
periplasmic domain were used to favour crystallization. Crystals were flash-frozen in liquid nitrogen 
after a brief immersion in the precipitation solution supplemented with 20 % (v/v) glycerol as 
cryoprotectant. Data were collected under cryogenic conditions on beamline ID30B at ESRF (Grenoble, 
France) on a Pilatus3 6M detector. Images were integrated with Imosflm (51) and scaled with Aimless 
from the CCP4 suite (52). Structure was refined by molecular replacement with Phaser (53) using the 
wild-type LolC periplasmic domain structure (5NAA) as the molecular replacement probe. The atomic 
model was manually built in Coot (54) and refined with Refmac (55) using NCS restraints.  
 
Structure depositions 
Structures were deposited in the Protein DataBank with accession codes 6F3Z (LolA·LolC complex), 
6F49 (LolC ΔHook), and 6FHM (LolA F47E variant). 
 
Measurement of LolCDE ATPase activity 
The ATPase activity of LolCDE proteins was evaluated using the EnzCheck Phosphate Assay Kit 
(Thermofisher) that couples the release of inorganic phosphate to purine nucleoside phosphorylase 
(PNP) mediated breakdown of 2-amino-6-mercapto-7-methyl-purine riboside (MESG). One unit of PNP 
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enzyme was added to a reaction mix containing 50 mM Tris-HCl pH 7.5, 1 mM MgCl2, 0.1 mM azide, 
500 µM MgATP (saturating concentration), 200 µM MESG and 0.03 % DDM in a final volume of 350 
µL. The mixture was incubated for 3 minutes and the reaction initiated with addition of 1 µM LolCDE 
(wild-type or variant). The reaction was followed spectrophotometrically at 360 nm using a 
NanoPhotometer (Implen). Where indicated, the LolCDE inhibitor, Compound 2 (20), was added at 10 
or 100 µM in 1 % DMSO (final concentration) and compared to addition of 1 % DMSO alone. To assess 
the effect of LolA on LolCDE ATPase activity, 5 µM untagged LolA (a five-fold molar excess) was 
incubated with LolCDE for 3 minutes prior to initiation of the reaction. The rate of hydrolysis was 
calculated using GraFit 7.0.3 software from the slope of the initial linear phase of the reaction. A 
calibration curve obtained using known concentrations of phosphate was used to convert absorbance 
readings to meaningful units. 
 
Periplasmic targeting of LolC domain 
Overnight cultures of C43 (DE3) cells bearing plasmid pBAD18-pelBperiLolC or indicated variant were 
grown overnight at 37 ºC in LB supplemented with 0.5 % (v/v) glycerol and 100 µg/ml carbenicillin. 
Cultures were diluted to an OD600 of 0.02 in fresh medium and grown at 37ºC. After 45 minutes, 0.2 % 
(w/v) arabinose (final concentration) was added to induce protein expression and the growth followed 
by monitoring OD600 for a further 4 hours. To assess expression of the LolC constructs in the periplasm, 
cultures were inoculated as described above and centrifuged at 3000 g for 30 minutes at 4 ºC after 60 
minutes growth post-induction. Cells resuspended in 200 mM Tris, 500 mM sucrose, 1 mM EDTA, 
incubated on ice for 30 mins. Following centrifugation at 16000 g for 30 minutes at 4 ºC, the supernatant 
was taken as the extracytoplasmic fraction. Samples were resolved on SDS-PAGE, transferred to 
nitrocellulose membrane, and immunoblotted with anti-His (Qiagen) and a dye-conjugated Donkey anti-
mouse secondary (Licor) antibodies. Immunoblots were revealed using an Odyssey Licor fluorescence 
imager. 
 
IMAC-based LolA binding assay  
His-tagged LolC periplasmic domain (15 µM final concentration) in 20 mM Hepes pH 7.5, 150 mM 
NaCl, in a final volume of 250 µL was incubated with 100 µL of Ni-IMAC resin (Biorad) for 5 minutes 
in a microbatch spin column (Generon). Non-tagged LolA (15 µM final concentration) was then added. 
After a further 5 minutes, the resin was washed three times with 250 µL of buffer before elution of 
bound proteins with the same volume of buffer containing 250 mM imidazole. Eluted proteins were 
analysed on gradient SDS-PAGE gels with purified proteins as references. Interaction of His-tagged 
LolCDE with LolA was assessed in the same manner except that 0.01 % DDM was added to all buffers. 
To assess the effect of any endogenously bound nucleotide, LolCDE was incubated with 5 mM EDTA, 
the sample desalted and the experiment performed as described above. Where specified, 1 mM 
MgATPγS or MgATP (final concentration) were added during incubation, wash and elution steps. 
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Where indicated, 25 or 100 µM of Compound 2 inhibitor (21), dissolved in 1 % DMSO (final 
concentration), was incubated with the His-tagged protein prior to addition of LolA and the effect 
compared to addition of DMSO alone. To assess interaction between LolB and the LolC periplasmic 
domain, the binding assay was performed with His-tagged mature LolB and untagged LolC and 
compared to the interaction of His-tagged LolA with untagged LolC. 
 
Construction of LolCDE homology model 
The LolCDE homology model was built with assistance from the PHYRE2 server (62). LolD and the 
inner membrane helices of LolC and LolE were built using the MacB structures 5LIL and 5NIL as 
respective models for the closed and open state. The periplasmic domain of LolC comes from the 
LolA·LolC structure (6F3Z) in which LolC Sabre and Porter subdomains were split and separately 
aligned to corresponding Sabre and Porter domains of MacB in the open (5NIL) or closed state (5LIL). 
LolA was positioned according to the coordinates of the LolA·LolC structure (6F3Z) which was 
superposed onto the homology model Sabre subdomain. The periplasmic domain of LolE was built with 
PHYRE2 using the structure of LolC periplasmic domain (5NAA) as a template. The Sabre and Porter 
subdomains of LolE were separated and placed in the same manner described for those of LolC.  
 
Sequence alignments 
The multiple and structure alignment server PromalS3D (63) was used to align the amino acid sequences 
of LolC, LolE, LolF, MacB and PvdT. The nucleotide binding domain of MacB and PvdT proteins were 
excluded from the alignment. 
 
